{"mc5Experience": [{"client": "Achaogen", "brand": "ACHN-490", "indication": "Aminoglyocide", "scopeOfWork": "Manuscripts, Abstracts, Posters, Sci Comm Plan"}, {"client": "Astrazeneca", "brand": "Cefaroline", "indication": "Complicated skin & soft tissue infections, Community acquired pneumonia", "scopeOfWork": "Slide Deck"}, {"client": "Basilea", "brand": "Ceftobiprole", "indication": "Complicated S. aureus bacteremia", "scopeOfWork": "Manuscript"}, {"client": "GSK", "brand": "Altabax", "indication": "Skin infections", "scopeOfWork": "Advisory Board, Slide Decks, Manuscripts"}, {"client": "Spero", "brand": "Tebipenum", "indication": "Complicated urinary tract infections", "scopeOfWork": "Strategic & Tactical Plan"}, {"client": "Theravance", "brand": "Telavancin", "indication": "Hospital-acquired or ventilator-associated pneumonia, complicated skin and skin structure infections", "scopeOfWork": "Manuscripts, Abstracts, Posters, Pub Plan, Lexicon"}, {"client": "VenatoRX", "brand": "Cefepime", "indication": "", "scopeOfWork": "Strategic and Tactical Plan"}, {"client": "Assembly Bio", "brand": "Vebicorvir, ABI-H2158, ABI-H3733, ABI-4334, ABI-6250", "indication": "Chronic HBV/HDV infection", "scopeOfWork": "Manuscripts, Abstracts, Posters, Orals"}, {"client": "Assembly Bio", "brand": "ABI-1179, ABI-5366", "indication": "Genital herpes", "scopeOfWork": "Manuscripts, Abstracts, Posters, Orals"}, {"client": "Gilead (AS)", "brand": "Sofosbuvir/velpatasvir, GS-9857, GS-4224,  bulevirtide, tenofovir alafenamide, selgantolimod", "indication": "Chronic hepatitis (incl HBV, HBC, HDV)", "scopeOfWork": "Manuscripts, Abstracts, Posters, Orals, HEOR, Publication Plan Updates, Competitor Analysis, Gap Analysis, Encore Plan Management"}, {"client": "Gilead (AS)", "brand": "Lenacapavir", "indication": "HIV treatment and prevention", "scopeOfWork": "HEOR Manuscripts, Abstracts, Posters"}, {"client": "Gilead", "brand": "Presatovir", "indication": "RSV", "scopeOfWork": "Manuscripts"}, {"client": "Amgen", "brand": "Evenity (romosozumab-aqqg), Prolia (denosumab)", "indication": "Osteoporosis", "scopeOfWork": "Infographic, Patient Website"}, {"client": "Aastrom", "brand": "Lxmelocel-T", "indication": "Chronic limb ischemia", "scopeOfWork": "SciCom Plan, Lexicon"}, {"client": "Actelion", "brand": "Epoprostenal", "indication": "PAH", "scopeOfWork": "Manuscripts, Abstracts, Posters"}, {"client": "Amgen", "brand": "Repatha (Evolocumab)", "indication": "Hyperlipidemia", "scopeOfWork": "Manuscripts, Abstracts, Posters, Orals, Slide Decks, PLSPs, Patient Website Articles"}, {"client": "Amgen", "brand": "Olpasiran", "indication": "Lp(a) in ASCVD", "scopeOfWork": "Manuscripts, Slide Decks, SCP"}, {"client": "Daiichi Sankyo", "brand": "DS-1040", "indication": "Acute treatment for stroke", "scopeOfWork": "Manuscripts, Abstracts, Posters"}, {"client": "Daiichi Sankyo (ABC)", "brand": "Edoxaban", "indication": "Stroke prevention in AF, secondary prevention in VTE", "scopeOfWork": "Manuscripts, Abstracts, Posters, Slide Decks, HEOR, Literature Searches, Publication Planning, Strategic Planning, Advisory Board Support"}, {"client": "GSK", "brand": "Rythmal", "indication": "Atrial fibrillation", "scopeOfWork": "Speaker Training, Advisory Board, Sales Aid, Manuscript, Video & DVD, Dinner Meeting"}, {"client": "GSK", "brand": "Lovaza  (prescription-grade omega3)", "indication": "CV support (AF high tryglycerides)", "scopeOfWork": "Pub Plan, Manuscripts, Non-Peer Reviewed Articles"}, {"client": "Merck", "brand": "MK-2060", "indication": "Major CV thrombotic events in patients with ESRD", "scopeOfWork": "SciCom Plan, KOL Identification, Literature monitoring"}, {"client": "IONIS", "brand": "olezarsen", "indication": "FCS", "scopeOfWork": ""}, {"client": "IONIS", "brand": "donidolorasen", "indication": "HAE", "scopeOfWork": ""}, {"client": "Trevena", "brand": "TRV027", "indication": "Acute heart failure", "scopeOfWork": "Posters"}, {"client": "Akebia", "brand": "Vadadustat", "indication": "CDK induced anemia", "scopeOfWork": "Pub Plan, Abstracts, Posters, Manuscripts"}, {"client": "Amgen", "brand": "Dazodalibep", "indication": "Kidney transplant rejection", "scopeOfWork": "Oral presentation, manuscript"}, {"client": "Amgen", "brand": "Daxdilimab", "indication": "Lupus nephritis", "scopeOfWork": "Scientific Communication Platform"}, {"client": "Travere", "brand": "Sparsenten", "indication": "IgA nephropathy", "scopeOfWork": "Advisory Board Meetings"}, {"client": "Sanofi", "brand": "Renvela", "indication": "Dialysis dependent CKD, remove phosphorous", "scopeOfWork": "Regional Advisory Board Meetings"}, {"client": "ACELYRIN", "brand": "Izokibep", "indication": "Psoriatic arthritis, hidradenitis suppurativa", "scopeOfWork": "Abstracts, Posters, Oral Presentations, Gap Analysis, Scientific Communication Platform"}, {"client": "Amgen", "brand": "Daxdilimab", "indication": "Alopecia areata, discoid lupus", "scopeOfWork": "Scientific Communication Platform"}, {"client": "Amgen", "brand": "Fipaxalparant", "indication": "Diffuse cutaneous systemic sclerosis", "scopeOfWork": "Manuscripts, Oral presentation, 1-Pager"}, {"client": "Replimune", "brand": "RP1", "indication": "Skin cancer (melanoma, nonmelanoma)", "scopeOfWork": "Manuscripts, Astracts, Posters, Oral Presentations, White Papers"}, {"client": "Sun", "brand": "Aminolevulinic acid (Levulan)", "indication": "Actinic keratosis", "scopeOfWork": "Manuscripts, Abstracts, Posters, Slide Decks, Gap Analyses"}, {"client": "Sun", "brand": "Halcinonide", "indication": "Dermatoses", "scopeOfWork": "Manuscripts, Abstracts, Posters"}, {"client": "Sun (ABC)", "brand": "Micronized isotretinoin (Absorica LD)", "indication": "Severe nodular acne", "scopeOfWork": "Manuscripts, Abstracts, Posters, Dossier, Gap Analyses"}, {"client": "Sun", "brand": "Lidose isotretinoin (Absorica)", "indication": "Severe nodular acne", "scopeOfWork": "Manuscripts, Abstracts, Posters, Dossier, Gap Analyses"}, {"client": "Sun (ABC)", "brand": "Tildrakizumab", "indication": "Plaque psoraisis, psoriatic arthritis, ankylosing spondylitis", "scopeOfWork": "Strategic & Pub Planning, Manuscripts, Abstracts, Posters, Slide decks, Gap Analyses, Dossier, Lexicon"}, {"client": "Sun (ABC)", "brand": "Clascoterone cream 1%", "indication": "Acne vulgaris", "scopeOfWork": "Manuscripts, Abstracts, Posters, Slide Decks, Gap Analyses, Dossier, Lexicon"}, {"client": "Sun (ABC)", "brand": "Deuruxolitinib", "indication": "Alopecia areata", "scopeOfWork": "Abstracts, Posters, Slide Decks, Dossier"}, {"client": "Timber (ABC)", "brand": "Sitaxentan", "indication": "Scleroderma", "scopeOfWork": "Manuscripts, Abstracts, Posters"}, {"client": "Abivax", "brand": "ABX464", "indication": "Ulcerative colitis", "scopeOfWork": "Manuscript"}, {"client": "AlfaSigma", "brand": "Velusetrag", "indication": "Gastropareses", "scopeOfWork": "Manuscripts, Abstracts, Poster"}, {"client": "Baxter", "brand": "Plasma-Lyte A", "indication": "Gastroenteritis", "scopeOfWork": "Manuscripts, Slide Deck"}, {"client": "Exact Sciences/Avant", "brand": "Cologuard", "indication": "Colorectal screening", "scopeOfWork": "Posters"}, {"client": "Gilead", "brand": "Andecaliximab", "indication": "Crohn\u2019s/UC", "scopeOfWork": "Manuscript, Abstracts, Posters"}, {"client": "Gilead", "brand": "Filgotinib", "indication": "Crohn\u2019s/UC/IBD", "scopeOfWork": "Manuscripts, Abstracts, Poster"}, {"client": "NPS", "brand": "Teduglutide", "indication": "Short bowel syndrome", "scopeOfWork": "Response Letters, Slides"}, {"client": "Takeda", "brand": "Dexlansoprazole", "indication": "GERD", "scopeOfWork": "Manuscripts, Abstracts, Posters"}, {"client": "Takeda", "brand": "Lubiprostone", "indication": "IBS", "scopeOfWork": "Manuscripts"}, {"client": "Theravance", "brand": "Izencitinib (TD -1473)", "indication": "Ulcerative colitis", "scopeOfWork": "Manuscripts, Abstracts, Poster"}, {"client": "Theravance", "brand": "Velusetrag", "indication": "Gastropareses", "scopeOfWork": "Manuscripts, Abstracts, Poster"}, {"client": "Morphic Therapeutic", "brand": "MORF-057", "indication": "Ulcerative colitis", "scopeOfWork": "Manuscript, Poster"}, {"client": "BioMarin", "brand": "Roctavian (valoctocogene roxaparvcovec)", "indication": "AAV5 gene therapy for severe hemophilia A", "scopeOfWork": "Manuscripts, Including Clinical and HEOR"}, {"client": "BioMarin", "brand": "BMN 331", "indication": "AAV5 gene therapy for hereditary angioedema types I and II", "scopeOfWork": "Manuscripts, Abstracts, Posters, SCP"}, {"client": "BioMarin", "brand": "BMN 293", "indication": "AAV gene therapy for hypertrophic cardiomyopathy", "scopeOfWork": "Posters, SCP"}, {"client": "Bluebird Bio", "brand": "LentiD", "indication": "Congenital adrenal leukodystrophy", "scopeOfWork": "Editorial Support For Abstracts & Congress Presentations, Med Info Letters, Lit Monitoring, Manuscript Editorial Submission Support, FAQs, Advisory Board Support, Congress Booth Support, Infographics"}, {"client": "Bluebird Bio", "brand": "LentiGlobin", "indication": "B-thalassemia and sickle cell disease", "scopeOfWork": "Editorial Support For Abstracts & Congress Presentations, Med Info Letters, Lit Monitoring, Manuscript Editorial Submission Support, FAQs, Advisory Board Support, Congress Booth Support, Infographics"}, {"client": "Excision (AS)", "brand": "EBT-101", "indication": "CRISPR gene therapy/HIV", "scopeOfWork": "Manuscripts, Slides, Abstracts & Congress Presentations"}, {"client": "Talaris (AS)", "brand": "FRC001", "indication": "Allogenic stem cell therapy/ scleroderma, kidney transplant", "scopeOfWork": "Manuscripts, Abstracts, Posters, Med Affairs Booth Materials (Booth Design/Panels [Physical and Virtual], Handouts/1-pagers), Monographs, Slide Decks, FAQs, Ad Boards, Landscape Analysis, Pubs Gap Analysis, Scientific Communication Platform, Publication Plan, Lexicon"}, {"client": "Taysha (AS)", "brand": "AAV9 technology platform", "indication": "Gene therapy platform, GAN, GM2 Gangliosidosis, CLN1 Disease, SURF1, GM2, Rett, Angelman, SLC13A5", "scopeOfWork": "Pub Plan, Manuscripts, Dossiers, SCP, Lexicon"}, {"client": "NS Pharma", "brand": "Viltolarsen", "indication": "Exon skipping antisense oligonucleotide for Duchenne muscular dystrophy", "scopeOfWork": "Posters, Manuscripts, publication planning"}, {"client": "GSK", "brand": "Avodart", "indication": "Enlarged prostate", "scopeOfWork": "Round Table Meetings, Symposium, Speaker training, Manuscripts, Pub Plan"}, {"client": "Sun", "brand": "Yonsa", "indication": "mCRPC", "scopeOfWork": "Abstracts, Manuscripts, Literature Searches, Slide Decks, Publication Planning, Dossier, Gap analysis"}, {"client": "Daiichi Sankyo", "brand": "DS-1211", "indication": "PXE", "scopeOfWork": "Lit Monitoring, Manuscripts"}, {"client": "Daiichi Sankyo", "brand": "DS-8500", "indication": "Type 2 diabetes", "scopeOfWork": "SciCom Plan, Gap Analysis"}, {"client": "Merck", "brand": "MK-6024", "indication": "NASH/NAFLD", "scopeOfWork": "Scientific Communication Platform"}, {"client": "NPS", "brand": "Recombinant human hormone", "indication": "Hypoparathyroidism", "scopeOfWork": "Response Letters"}, {"client": "Opko", "brand": "Calcidfediol", "indication": "Vitamin D deficiency", "scopeOfWork": "Posters, Manuscripts (Not Completed), Trade Magazine Articles"}, {"client": "Relypsa", "brand": "Patiromer", "indication": "Hyperkalemia", "scopeOfWork": "Manuscripts, Abstracts, Posters, Congress Support, Gap Analysis, Pub Plan"}, {"client": "Sun (ABC)", "brand": "Utreglutide (GL0034)", "indication": "Type 2 diabetes, obesity", "scopeOfWork": "Posters"}, {"client": "Takeda", "brand": "Alogliptin", "indication": "Type 2 diabetes", "scopeOfWork": "Manuscripts"}, {"client": "Takeda", "brand": "Fasiglifam", "indication": "Type 2 diabetes", "scopeOfWork": "Manuscripts"}, {"client": "Currax", "brand": "Contrave", "indication": "Obesity", "scopeOfWork": "Manuscripts, advisory (editorial) board, tactical pub plan"}, {"client": "BioMarin", "brand": "Palynziq, Kuvan", "indication": "PKU", "scopeOfWork": "SCP"}, {"client": "BioMarin", "brand": "Voxzogo", "indication": "Achondroplasia, hypochondroplasia, idiopathic short stature", "scopeOfWork": "Abstracts, manuscripts, posters"}, {"client": "Adamas/Supernus", "brand": "Amantadine", "indication": "Parkinson's", "scopeOfWork": "Manuscripts, Posters, Slide Decks, Pub Plan, Med Info letters"}, {"client": "Supernus", "brand": "Apomorphine", "indication": "Parkinson's", "scopeOfWork": "Manuscripts"}, {"client": "Supernus", "brand": "Qelbree", "indication": "ADHD", "scopeOfWork": "Revisions, Publication Plan"}, {"client": "Supernus", "brand": "NV-5138", "indication": "Treatment-resistant depression", "scopeOfWork": "Revisions, Publication Plan"}, {"client": "Camurus", "brand": "CAM 2038", "indication": "Opioid addiction/pain", "scopeOfWork": "Manuscript"}, {"client": "Amgen", "brand": "Erenumaub", "indication": "Migraines", "scopeOfWork": "Review Manuscript, Med Info Letter"}, {"client": "Braeburn", "brand": "All", "indication": "Opioid addiction", "scopeOfWork": ""}, {"client": "Braeburn", "brand": "CAM 2038", "indication": "", "scopeOfWork": ""}, {"client": "Braeburn", "brand": "Probuphine", "indication": "Implants", "scopeOfWork": "Manuscripts, Abstracts, Posters, Training Slide Deck"}, {"client": "Braeburn", "brand": "Risperidone", "indication": "Implants", "scopeOfWork": "Manuscripts, Abstracts, Posters, Training Slide Deck"}, {"client": "Neos", "brand": "Amphetamis and Methylphenidate", "indication": "ADHD", "scopeOfWork": "Manuscripts, Abstracts, Posters, Slide Desks, Speaker Training, Payors, Pub Plan, Slide Compendium"}, {"client": "Osmotica", "brand": "Amantadine", "indication": "Idiopathic Parkinson's", "scopeOfWork": "Manuscripts, Strategic & Tactical Plan, Clinical Dossier (AMCP Format) Scientific Platform"}, {"client": "Osmotica", "brand": "Arbaclofen", "indication": "Muscle spasticity in MS", "scopeOfWork": "Slides"}, {"client": "MAPS PBC", "brand": "MDMA", "indication": "PTSD", "scopeOfWork": "Manuscripts"}, {"client": "Sage (ABC)", "brand": "Brexanalone", "indication": "PPD", "scopeOfWork": "Manuscripts, Posters, Abstracts, Landscape Analysis"}, {"client": "Sage (ABC)", "brand": "Zuranalone (MDD)", "indication": "MDD and PPD", "scopeOfWork": "Manuscripts, Posters, Abstracts, Landscape Analysis"}, {"client": "Teva (AQ)", "brand": "TV-46000 (long-acting injectable risperidone)", "indication": "Schizophrenia in adults", "scopeOfWork": "Medical Outcomes Liaison slide decks; FAQs; AMCP Dossiers"}, {"client": "Sun (ABC)", "brand": "sezaby", "indication": "neonatal seizures", "scopeOfWork": "lit monitoring, review manuscript, pub planning, MSL decks, med info"}, {"client": "Scholar Rock", "brand": "apitegromab", "indication": "Spinal muscular atrophy", "scopeOfWork": "Abstract"}, {"client": "BioMarin", "brand": "BMN 351", "indication": "Duchenne muscular dystrophy", "scopeOfWork": "Manuscripts, posters, oral presentation, SCP"}, {"client": "XW Pharma", "brand": "XW10172, GABA-B agonist", "indication": "Sleep", "scopeOfWork": "Manuscript"}, {"client": "Aadi Bioscience", "brand": "nab-Sirolimus", "indication": "PEComa, solid tumors with TSC1/TSC2 alterations", "scopeOfWork": "Abstracts, Posters, Preclinical Manuscript"}, {"client": "Adastra (ABC)", "brand": "Zotiracicib", "indication": "Glioblastoma & medullablastoma", "scopeOfWork": "Regulatory Document"}, {"client": "Amgen", "brand": "Denosumab", "indication": "Skeletal, giant cell tumor of bone", "scopeOfWork": "Fact Sheets"}, {"client": "Amgen", "brand": "Pegfilgastim/", "indication": "Hematologic support", "scopeOfWork": "Med Info Letters, Fact Sheets"}, {"client": "Arvinas", "brand": "Vepdegestrant", "indication": "ER+/HER2- Advanced Breast Cancer", "scopeOfWork": "Manuscripts, abstracts, posters, oral presentations, plain language summaries, SCP, MSL training decks, MSL field materials, infographics, interactive PDFs, MOA videos"}, {"client": "Arvinas", "brand": "Bavdegalutamide", "indication": "Metastatic Castration-Resistant Prostate Cancer", "scopeOfWork": "Manuscripts"}, {"client": "Arvinas", "brand": "ARV-393", "indication": "Non-Hodgkin Lymphoma", "scopeOfWork": "Abstracts, posters, SCP, MSL field materials, infographics, interactive PDFs, MOA videos"}, {"client": "Caribou Biosciences", "brand": "CB-010", "indication": "Engineered CAR-T cell therapy for Non-Hodgkin Lymphoma", "scopeOfWork": "Platform, Lexicon"}, {"client": "Caribou Biosciences", "brand": "CB-011", "indication": "Engineered CAR-T cell therapy for Multiple Myeloma", "scopeOfWork": "Platform, Lexicon, Preclinical manuscript"}, {"client": "Caribou Biosciences", "brand": "CB-012", "indication": "Engineered CAR-T cell therapy for Acute Myeloid Leukemia", "scopeOfWork": "Platform, Lexicon"}, {"client": "Caribou Biosciences", "brand": "CB-020", "indication": "Engineered CAR-NK cell therapy for solid tumors", "scopeOfWork": "Platform, Lexicon"}, {"client": "Daiichi Sankyo", "brand": "DS-1205", "indication": "Metastatic small cell lung cancer", "scopeOfWork": "Poster"}, {"client": "Daiichi Sankyo", "brand": "DS-8201", "indication": "HER-2 expressing solid tumors (breast, gastric, small cell, lung, others)", "scopeOfWork": "Manuscripts, Abstracts, Posters, Slide Decks, Strategic Platform, Lit Monitoring, Gap Analysis, Strategic & Pub Planning, Conference Support"}, {"client": "Daiichi Sankyo", "brand": "U3- 1402", "indication": "HER3- expressing solid tumors", "scopeOfWork": "Abstracts, Posters, Manuscripts"}, {"client": "Deciphera", "brand": "Vimseltinib", "indication": "Tenosynovial giant cell tumors", "scopeOfWork": "Posters, Slide Decks, Abstracts, Manuscripts, Infographics, Scientific Communication Platform, Plain Language Summaries, Med Affairs Training Decks, MSL Materials"}, {"client": "Deciphera", "brand": "Rebastinib (discontinued)", "indication": "Solid tumors", "scopeOfWork": "Posters, SCP"}, {"client": "Deciphera", "brand": "DCC-3116", "indication": "Solid tumors", "scopeOfWork": "Abstracts, posters/presentations, Scientific Communication Platform, patient advocacy deck"}, {"client": "Deciphera", "brand": "Ripretinib (QINLOCK)", "indication": "Gastrointestinal stromal tumors", "scopeOfWork": "Posters, Slide Decks, Abstracts, Manuscripts, Infographics, Scientific Communication Platform, Plain Language Summaries, SIUU materials"}, {"client": "Deciphera", "brand": "DCC-3009", "indication": "Gastrointestinal stromal tumors", "scopeOfWork": "Abstracts, Posters/Presentations, Scientific Communication Platform, Preclinical Posters"}, {"client": "Deciphera", "brand": "DCC-3084", "indication": "Solid tumors", "scopeOfWork": "Abstracts, Posters, SCP"}, {"client": "Deciphera", "brand": "DP-9149", "indication": "Solid tumors", "scopeOfWork": "Posters"}, {"client": "Gilead", "brand": "Acalisib", "indication": "Relapsed or refractory lymphoid malignancies (failed)", "scopeOfWork": "Manuscript"}, {"client": "Gilead", "brand": "Cell therapy", "indication": "Lymphomas", "scopeOfWork": "Advisory Board"}, {"client": "Gilead", "brand": "Idelalisib", "indication": "Relapsed chronic lymphocytic leukemia, relapsed folliciular B-cell, non Hodgkins lymphoma", "scopeOfWork": "Manuscripts, Abstracts, Posters"}, {"client": "Gilead", "brand": "Momelotinib", "indication": "Myelofibrosis", "scopeOfWork": "Strategic Plan, Manuscript"}, {"client": "Gilead", "brand": "Simtuzumab", "indication": "Solid tumors", "scopeOfWork": "Manuscripts"}, {"client": "Gilead", "brand": "Tirabrutinib", "indication": "Hematologic oncology", "scopeOfWork": "Manuscripts (Not Started Yet)"}, {"client": "Gilead (AS)", "brand": "Magrolimab", "indication": "CLL, MDS", "scopeOfWork": "Manuscripts, Abstracts (encores), Advisory Boards"}, {"client": "Gilead (AS)", "brand": "Sacitizumab govitecan", "indication": "multiple tumor types", "scopeOfWork": "Encore abstracts"}, {"client": "Janssen", "brand": "Abiraterone", "indication": "Castration-resistant prostate cancer", "scopeOfWork": "Advisory Board Meetings (For Publications), Manuscripts"}, {"client": "Janssen", "brand": "Ibrutinib", "indication": "Diffuse large B cell lymphoma", "scopeOfWork": "Abstracts, Manuscripts"}, {"client": "Janssen", "brand": "Siltuximab", "indication": "Relapsed multiple myeloma", "scopeOfWork": "Manuscript"}, {"client": "Replimune", "brand": "RPx", "indication": "Skin cancer, solid tumors", "scopeOfWork": "Posters, Review and Primary Manuscripts, oral presentations, white papers"}, {"client": "Sun", "brand": "Abiraterone acetetate", "indication": "Prostate cancer", "scopeOfWork": "Abstracts, Manuscripts, Literature Searches, slide decks, Dossier, Pub Planning, gap analysis, med info letters"}, {"client": "Sun", "brand": "Gemcitabine", "indication": "", "scopeOfWork": "Manuscript"}, {"client": "Sun", "brand": "Octreotide acetate", "indication": "Symptoms of carcinoid tumors, vasoactive intestinal peptide tumors", "scopeOfWork": "manuscript"}, {"client": "Sun", "brand": "Sonidegib", "indication": "Advanced basal cell carcinoma", "scopeOfWork": "Manuscripts, Posters, MSL, Slide Desk, Publication Planning, Literature Searches, Dossier, gap analysis, med info letters"}, {"client": "Scholar Rock", "brand": "Linavonkibart", "indication": "Solid tumors resistant to immune checkpoint blockade (ICI)", "scopeOfWork": "Manuscripts, posters"}, {"client": "ACELYRIN", "brand": "Lonigutamab", "indication": "Thyroid eye disease", "scopeOfWork": "Abstracts, Oral Presentations, posters, SCP, gap analysis, congress handouts, publication planning, manuscripts"}, {"client": "Amgen", "brand": "Teprotumamab", "indication": "Thyroid eye disease", "scopeOfWork": "Manuscripts, Posters"}, {"client": "Osmotica (ABC)", "brand": "RevitaLid (oxymetazoline HCL)", "indication": "Ptosis", "scopeOfWork": "Manuscripts, Abstracts, Slides"}, {"client": "Sun", "brand": "Bromsite", "indication": "Glaucoma & ocular hypertension", "scopeOfWork": "Med info letters, MSL slide decks"}, {"client": "Sun", "brand": "Xelpros (latanoprost)", "indication": "Glaucoma & ocular hypertension", "scopeOfWork": "Manuscripts, Abstracts, Posters, MSL Slide Decks, Monthly Internal Pub Meetings, med info lettesr"}, {"client": "Sun (ABC)", "brand": "OTX-101 (cyclosporine)", "indication": "Dry eye disease", "scopeOfWork": "Strategic & Pub Plan, Manuscripts, Abstract, Posters, Slide Deck (Congress Presentations, MSL Decks, Monthly Internal Pub Meetings), Lexicon, Gap Analysis, Lit Searches, Dossier, Med info letters"}, {"client": "Daiichi Sankyo", "brand": "Abuse-deterrent opioids (Roxybond&  Morphabond ER)", "indication": "", "scopeOfWork": "Virtual Advisory Board"}, {"client": "Daiichi Sankyo", "brand": "CL-108", "indication": "Opioid-induced nausea and vomiting", "scopeOfWork": "Manuscripts, Abstracts, Posters, Literature Searches"}, {"client": "Daiichi Sankyo", "brand": "Mirogabalin", "indication": "Postherpetic pain, diabetic peripheral neuropathic pain, fibromyalgia (failed)", "scopeOfWork": "Gap Analysis, Strategic & Pub Plans, Scientific Platoform, Manuscripts, Abstracts, Posters, Internal Team Support"}, {"client": "Camurus", "brand": "CAM 2038", "indication": "", "scopeOfWork": "Manuscript"}, {"client": "Flexion", "brand": "Zilretta", "indication": "Osteoarthritis", "scopeOfWork": "Strategic Plan, Manuscript, Dossier Slides"}, {"client": "Iroko", "brand": "Reformulated NSAIDs", "indication": "", "scopeOfWork": "Pub Plan, Abstracts, Posters, Manuscripts, Advisory Board, Med Info Letterts, White Papers, Compendium"}, {"client": "Trevena", "brand": "TRV130 IV opioid", "indication": "Acute pain", "scopeOfWork": "Abstracts, Poster, Manuscript"}, {"client": "Trevena", "brand": "TRV734", "indication": "Oral opioid", "scopeOfWork": "Abstracts"}, {"client": "Amgen", "brand": "UPLIZNA (inebilizumab-cdon)", "indication": "NMOSD, IgG4-RD, myasthenia gravis", "scopeOfWork": "Manuscripts, Posters, Oral presentation, Brochures, Brief Communications, Reviews, PLSPs, MILs, Slide decks"}, {"client": "BioMarin", "brand": "Roctavian (valoctocogene roxaparvcovec)", "indication": "Severe hemophilia A", "scopeOfWork": "Abstracts, posters, presentations, and manuscripts, including preclinical, clinical, HEOR, and plain language"}, {"client": "BioMarin", "brand": "BMN 331", "indication": "Hereditary angioedema types I/II", "scopeOfWork": "Manuscripts, abstracts, posters, SCP"}, {"client": "BioMarin", "brand": "BMN 351", "indication": "Duchenne muscular dystrophy", "scopeOfWork": "Manuscripts, posters, oral presentation, SCP"}, {"client": "BioMarin", "brand": "Palynziq (pegvaliase)", "indication": "PKU", "scopeOfWork": "SCP"}, {"client": "BioMarin", "brand": "BMN 293", "indication": "Hypertrophic cardiomyopathy", "scopeOfWork": "Posters, SCP"}, {"client": "BioMarin", "brand": "Vosoritide", "indication": "Achondroplasia", "scopeOfWork": "Poster"}, {"client": "BioMarin", "brand": "Voxzogo", "indication": "Achondroplasia, hypochondroplasia, idiopathic short stature", "scopeOfWork": "Abstracts, manuscripts, posters"}, {"client": "BioMarin", "brand": "BMN 349", "indication": "Alpha-1 anitrypsin deficiency", "scopeOfWork": "Manuscripts, SCP"}, {"client": "Bluebird Bio", "brand": "LentiD", "indication": "Congenital adrenbal leukodystrophy", "scopeOfWork": "Editorial Support For Abstracts & Congress Presentations, Med Info Letters, Lit Monitoring, Manuscript Editorial Submission Support, FAQs, Advisory Board Support, Congress Booth Support, Infographics"}, {"client": "Bluebird Bio", "brand": "LentiGlobin", "indication": "B-thalassemia and sickle cell disease", "scopeOfWork": "Editorial Support For Abstracts & Congress Presentations, Med Info Letters, Lit Monitoring, Manuscript Editorial Submission Support, FAQs, Advisory Board Support, Congress Booth Support, Infographics"}, {"client": "Blueprint Medicines", "brand": "Avapritinib", "indication": "Advanced systemic mastocytosis, indolent systemic mastocytosis", "scopeOfWork": "Manuscripts, posters"}, {"client": "CSL Behring", "brand": "Hizentra", "indication": "Chronic inflammatory", "scopeOfWork": "Strategic Plan (Never Finalized)"}, {"client": "Daiichi Sankyo (ABC)", "brand": "DS-1211", "indication": "PXE", "scopeOfWork": "Lit Monitoring, Manuscripts"}, {"client": "Ionis", "brand": "Zilganersen", "indication": "Alexander Disease", "scopeOfWork": "Scientific Communication Platform"}, {"client": "Ionis", "brand": "ION717", "indication": "Prion disease", "scopeOfWork": "Scientific Communication Platform"}, {"client": "Ionis", "brand": "Olezarsen", "indication": "Familial chylomicronemia", "scopeOfWork": "Manuscript"}, {"client": "NS Pharma", "brand": "Viltolarsen", "indication": "Duchenne muscular dystrophy", "scopeOfWork": "Abstracts, Posters, Manuscripts, Slide Decks, Oral Presentations"}, {"client": "NS Pharma", "brand": "NS-089", "indication": "Duchenne muscular dystrophy", "scopeOfWork": "Abstracts, Posters"}, {"client": "NS Pharma", "brand": "NS-050", "indication": "Duchenne muscular dystrophy", "scopeOfWork": "Abstracts, Posters"}, {"client": "Grifols", "brand": "Prolastin C", "indication": "Alpha 1 - anitrypsin deficiency", "scopeOfWork": "Pub Plan, Centers of Excellence"}, {"client": "Talaris (AS)", "brand": "FRC001", "indication": "Allogenic stem cell therapy/ scleroderma, kidney transplant", "scopeOfWork": "Manuscripts, Abstracts, Posters, Med Affairs Booth Materials (Booth Design/Panels [Physical and Virtual], Handouts/1-pagers), Monographs, Slide Decks, FAQs, Ad Boards, Landscape Analysis, Pubs Gap Analysis, Scientific Communication Platform, Publication Plan, Lexicon"}, {"client": "Taysha (AS)", "brand": "AAV9 technology platform", "indication": "Gene therapy platform, GAN, GM2 Gangliosidosis, CLN1 Disease, SURF1, GM2, Rett, Angelman, SLC13A5", "scopeOfWork": "Pub Plan, Manuscripts, Dossiers, SCP, Lexicon"}, {"client": "Theravance", "brand": "Ampreloxetine", "indication": "Neurogenic orthostatic hypotension", "scopeOfWork": "Oral presentions, Posters"}, {"client": "Scholar Rock", "brand": "Apitegromab", "indication": "Spinal muscular atrophy", "scopeOfWork": "Abstracts, posters, manuscripts, SCP, presentations"}, {"client": "Timber (ABC)", "brand": "Isotretinoin", "indication": "Congenital ichthyosis", "scopeOfWork": "Abstracts, Posters, Manuscripts"}, {"client": "Vertex", "brand": "Ivacaftor and VX-661", "indication": "Cystic fibrosis", "scopeOfWork": "Manuscripts, Posters, Slides"}, {"client": "Atea", "brand": "AT-527", "indication": "COVID-19 disease", "scopeOfWork": "KOL ID, Abstracts (Posters), Advisory Board"}, {"client": "Gilead", "brand": "Simtuzumab", "indication": "Idiopathic pulmonary fibrosis", "scopeOfWork": "Manuscripts, Abstract"}, {"client": "Grifols", "brand": "Prolastin C", "indication": "Alpha 1 - anitrypsin deficiency", "scopeOfWork": "Pub Plan, Centers of Excellence"}, {"client": "Amgen", "brand": "Fipaxalparant", "indication": "Idiopathic pulmonary fibrosis", "scopeOfWork": "Manuscripts, Oral Presentation, SCP, 1-Pager"}, {"client": "Theravance", "brand": "Nezulcitinib", "indication": "Acute lung injury, COVID 19", "scopeOfWork": "Pub Plan"}, {"client": "Theravance", "brand": "Revefenacin", "indication": "COPD, asthma", "scopeOfWork": "Manuscripts (post-submission reformats and de novo), Poster"}, {"client": "Theravance", "brand": "TD-1058", "indication": "ALK5 inhibitor", "scopeOfWork": "Manuscripts, Posters, Slide Decks, Abstracts, Oral Presentations"}, {"client": "Theravance", "brand": "TD-8236", "indication": "Asthma", "scopeOfWork": "Abstracts, Posters, Slide Decks"}, {"client": "Vertex", "brand": "Ivacftor and VX-661", "indication": "Cystic fibrosis", "scopeOfWork": "Manuscripts, Posters, Slides (Congress Presentations)"}, {"client": "ACELYRIN", "brand": "Izokibep", "indication": "Psoriatic arthritis", "scopeOfWork": "Manuscript, Abstracts, Posters, Oral Presentations, Scientific Communication Platform, Gap Analysis"}, {"client": "Daiichi Sankyo", "brand": "DS-7011a", "indication": "Systemic lupus erythematosus", "scopeOfWork": "Posters"}, {"client": "Gilead", "brand": "Andecaliximab", "indication": "RA", "scopeOfWork": "Manuscripts"}, {"client": "Gilead", "brand": "Filgotinib", "indication": "RA", "scopeOfWork": "Manuscripts, Abstracts, Posters, HEOR, PRO competitor analysis"}, {"client": "Amgen", "brand": "Daxdilimab, AMG 329", "indication": "Systemic lupus erythematosus, lupus nephritis", "scopeOfWork": "Scientific Communication Platform, Brief Communication, Posters, Abstracts"}, {"client": "Amgen", "brand": "Dazodalibep, AMG 329", "indication": "Sjogren's", "scopeOfWork": "Scientific Communication Platform, PLSP, Slide Decks, Lexicon, Manuscripts, Posters"}, {"client": "Amgen", "brand": "Krystexxa (pegloticase)", "indication": "Gout", "scopeOfWork": "Manuscripts, Posters"}, {"client": "Moebius Medical", "brand": "MM-II", "indication": "Osteoarthritis", "scopeOfWork": "Manucripts, abstracts, posters, presentations"}, {"client": "Sun (ABC)", "brand": "Tildrakizumab", "indication": "Plaque psoraisis, psoriatic arthritis, ankylosing spondylitis", "scopeOfWork": "Strategic & Pub Plan, Manuscripts, Abstracts, Posters, Literature Searches, Dossier"}, {"client": "Takeda", "brand": "Colchicine (Colcrys)", "indication": "Gout", "scopeOfWork": "Manuscripts"}, {"client": "Takeda", "brand": "Febuxostat (Uloric)", "indication": "Gout", "scopeOfWork": "Gap Analysis, Pub Plan, Manuscripts, Abstracts, Posters"}, {"client": "Dynavax", "brand": "Hepatitis B Vaccine", "indication": "", "scopeOfWork": "Advisory Board"}, {"client": "GSK", "brand": "Cervarix", "indication": "Prevention of HPV infection", "scopeOfWork": "Manuscripts, Advisory Boards, Slides, Speaker Training, Congress Support, Pub Plans"}, {"client": "GSK", "brand": "Menhibrix", "indication": "Meningitis & HiB", "scopeOfWork": "Manuscripts, Pub plans"}, {"client": "GSK", "brand": "Twinrix", "indication": "Hepatitis A & B", "scopeOfWork": "Manuscripts, Slide Decks, AANP Promotional Program, Video Development"}, {"client": "Novartis", "brand": "Menveo", "indication": "Meningoccal", "scopeOfWork": "Speaker Training"}, {"client": "Arbo Vita", "brand": "HPV E6", "indication": "Cervical cancer screening", "scopeOfWork": "Slide Deck"}, {"client": "Becton Dickinson", "brand": "SurePath", "indication": "HPV testing", "scopeOfWork": "Advisory Board, Investigator Meeting"}, {"client": "Hologic", "brand": "Adiana", "indication": "Permanent contraception", "scopeOfWork": "Posters, Slide Decks, Manuscripts"}, {"client": "Hologic", "brand": "Cervista", "indication": "HR HPV screening", "scopeOfWork": "Manuscripts, Abstracts, Posters, Speaker Training, Pub Pans, Advisory Board, Newsletters"}, {"client": "Hologic", "brand": "Liquid based cytology", "indication": "Cervical cancer screening", "scopeOfWork": "Dossiers, Toolkits, Letters to Editor In Response To Guideline Releases, Payor Slides"}, {"client": "Hologic", "brand": "Novasure", "indication": "Endometrial ablation for abnormal uterine bleeding", "scopeOfWork": "Manuscripts, Posters, Round Table Meetings, Response Letters, Advisory Board, Binders"}, {"client": "Sebela (AQ)", "brand": "VeraCept (Miudella)", "indication": "Hormone-free, low-dose copper IUD", "scopeOfWork": "Core Value Dossier, Scientific Communication Platform & Lexicon, KOL Identification/Engagement Plan, MSL Slide Deck, Scientific Communication Plan, HEOR Manuscripts, Abstracts, Posters, Budget Impact Model"}, {"client": "BioMarin", "brand": "BMN 349", "indication": "Alpha-1 anitrypsin deficiency", "scopeOfWork": "Manuscripts, SCP"}, {"client": "Gilead", "brand": "Seladelpar (Livdelzi)", "indication": "Primary biliary cholangitis", "scopeOfWork": "Abstracts, posters, oral presentations, manuscripts, plain language summaries, scientific platforms"}], "outsideAgencyExperience": [{"diseaseState": "Diabetes", "company": "Novo Nordisk", "drugName": "Victoza", "drugMoa": "GLP-1 agonist", "experience": "2 years", "previousAgency": "all of these were with the Adelphi Group"}, {"diseaseState": "Obesity", "company": "Novo Nordisk", "drugName": "Victoza", "drugMoa": "GLP-1 agonist", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Hypercholesterolemia", "company": "Pfizer", "drugName": "Lipitor", "drugMoa": "HMG-CoA reductase inhibitor", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Hypertension", "company": "Pfizer", "drugName": "Norvasc", "drugMoa": "Ca channel blocker", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Major depressive disorder", "company": "Pfizer", "drugName": "Zoloft", "drugMoa": "SSRI", "experience": "5 years", "previousAgency": ""}, {"diseaseState": "Epilepsy", "company": "Pfizer", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years", "previousAgency": ""}, {"diseaseState": "Neuropathic pain", "company": "Pfizer", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years", "previousAgency": ""}, {"diseaseState": "Generalized anxiety disorder", "company": "Pfizer", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years", "previousAgency": ""}, {"diseaseState": "Fibromyalgia", "company": "Pfizer", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years", "previousAgency": ""}, {"diseaseState": "Schizophrenia", "company": "Pfizer", "drugName": "Geodon", "drugMoa": "Atypical antopsychotic", "experience": "6 months", "previousAgency": ""}, {"diseaseState": "Alzheimer's Disease", "company": "Eisai /Pfizer", "drugName": "Aricept", "drugMoa": "Central acetylcholinesterase inhibitor", "experience": "1.5 years", "previousAgency": ""}, {"diseaseState": "Rheumatoid arthritis", "company": "Sanofi Regeneron", "drugName": "Kevzara", "drugMoa": "IL-6 mAb", "experience": "1 years", "previousAgency": ""}, {"diseaseState": "Rheumatiod arthritis", "company": "Galapagos", "drugName": "Jyseleca", "drugMoa": "JAK inhibitor", "experience": "2.75 years", "previousAgency": "my work on Jyseleca was done at AlphaBioCom for Gilead. We still support Jyseleca via Gilead Japan"}, {"diseaseState": "Overactive bladder", "company": "Astellas", "drugName": "Vesicare", "drugMoa": "Bladder-specific antimuscarinic", "experience": "5 years", "previousAgency": ""}, {"diseaseState": "Pulmonary hypertension", "company": "Bayer", "drugName": "Adempas", "drugMoa": "Soluble guanylate cyclase stimulator", "experience": "4 years", "previousAgency": ""}, {"diseaseState": "Osteoporosis", "company": "Radius", "drugName": "Tymlos", "drugMoa": "Parathyroid hormone-related protein analog", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Allergic rhinitis", "company": "Merck", "drugName": "Nasonex", "drugMoa": "Corticosteroid", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Allergic rhinitis", "company": "Merck", "drugName": "Claritin", "drugMoa": "Antihistamine", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Allergic rhinitis", "company": "Merck", "drugName": "Grastek, Ragwitek", "drugMoa": "Oral immunotherapy", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "COPD", "company": "Merck", "drugName": "Dulera", "drugMoa": "Corticosteroid/LABA", "experience": "1 years", "previousAgency": ""}, {"diseaseState": "Asthma", "company": "Merck", "drugName": "Asmanex; Dulera", "drugMoa": "Corticosteroid; corticosteroid/LABA", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Jane Kovalevich", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Myeloproliferative neoplasms", "company": "Incyte", "drugName": "Jakafi", "drugMoa": "JAK1/JAK2 inhibitor", "experience": "5 years", "previousAgency": ""}, {"diseaseState": "GVHD (acute and chronic)", "company": "Incyte", "drugName": "Jakafi", "drugMoa": "JAK1/JAK2 inhibitor", "experience": "5 years", "previousAgency": ""}, {"diseaseState": "Atopic Dermatitis", "company": "Abbvie", "drugName": "Opzelura", "drugMoa": "Topical JAK1/JAK2 inhibitor", "experience": "4 years", "previousAgency": ""}, {"diseaseState": "Vitiligo", "company": "Abbvie", "drugName": "Opzelura", "drugMoa": "Topical JAK1/JAK2 inhibitor", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Hidradenitis suppurativa", "company": "Incyte", "drugName": "Povorcitinib", "drugMoa": "JAK1 inhibitor", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Autoimmune hemolytic anemia", "company": "Incyte", "drugName": "Parsaclisib", "drugMoa": "PI3K delta inhibitor", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Melanoma, solid tumors", "company": "Incyte", "drugName": "Epacadostat", "drugMoa": "IDO1 inhibitor", "experience": "1.5 years", "previousAgency": ""}, {"diseaseState": "Oncology (solid tumors, hematologic cancers)", "company": "Incyte", "drugName": "Itacitinib", "drugMoa": "JAK1 inhibitor", "experience": "4 years", "previousAgency": ""}, {"diseaseState": "COVID-19", "company": "GSK", "drugName": "Ruxolitinib", "drugMoa": "JAK1/JAK2 inhibitor", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Cholangiocarcinoma", "company": "Incyte", "drugName": "Pemazyre", "drugMoa": "FGFR1-3 inhibitor", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "MLN with FGFR1 rearrangement", "company": "Taiho Oncology", "drugName": "Pemigatinib", "drugMoa": "FGFR1-3 inhibitor", "experience": "1 year", "previousAgency": ""}, {"diseaseState": "Francesca Hemingway", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Diabetes", "company": "Novo Nordisk", "drugName": "Insulin degludec (Tresiba)/ Insulin degludec + insulin aspart (Ryzodeg)/ Insulin detemir (Levemir)", "drugMoa": "Insulin", "experience": "10 years", "previousAgency": ""}, {"diseaseState": "Diabetes/cardiovascular outcomes", "company": "Novo Nordisk", "drugName": "Insulin degludec (Tresiba)", "drugMoa": "Insulin", "experience": "5 years", "previousAgency": ""}, {"diseaseState": "Diabetes", "company": "Novo Nordisk", "drugName": "Insulin degludec + liraglutide (Xultophy)", "drugMoa": "Insulin/GLP-1 receptor agonist combination", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Multiple sclerosis", "company": "Merck", "drugName": "Evobrutinib", "drugMoa": "BTK inhibitor", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "SLE", "company": "Merck", "drugName": "Enpatoran", "drugMoa": "TLR7/8 antagonist", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Diabetes", "company": "Novo Nordisk", "drugName": "Liraglutide (Victoza)", "drugMoa": "GLP-1 receptor agonist", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Oncology (solid tumors)", "company": "Merck", "drugName": "M6223", "drugMoa": "anti-TIGIT monoclonal antibody", "experience": "1.5 years", "previousAgency": ""}, {"diseaseState": "Oncology", "company": "Mundipharma", "drugName": "Leuprorelin (Eligard)", "drugMoa": "GnRH analogue", "experience": "1 year", "previousAgency": ""}, {"diseaseState": "Oncology (hematologic cancers)", "company": "Mundipharma", "drugName": "Ibritumomab tiuxetan (Zevalin)/ Pralatrexate (Folotyn)", "drugMoa": "Monocloncal antibody/folate analogue inhibitor", "experience": "1 year", "previousAgency": ""}, {"diseaseState": "Women's fertility/menopause", "company": "Novo Nordisk", "drugName": "Estradiol (Vagifem)", "drugMoa": "Vaginal insert", "experience": "0.5 year", "previousAgency": ""}, {"diseaseState": "Ellie Manca", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Oncology (solid tumor, ovarian cancer)", "company": "Abbvie", "drugName": "mirvetuximab soravtansine (ELAHERE)", "drugMoa": "antibody-drug conjugate", "experience": "2 years; all Pubs, SCP/IEP workshops, MSL decks, PI exam, commercial congress coverage, advisory boards and summaries", "previousAgency": "PRECISION AQ"}, {"diseaseState": "Oncology (hematologic, AML and BPDCN)", "company": "ImmunoGen", "drugName": "pivekimab sunirine", "drugMoa": "antibody-drug conjugate", "experience": "2 years; all Pubs, MSL decks", "previousAgency": "PRECISION AQ"}, {"diseaseState": "Virology (HIV)", "company": "Merck", "drugName": "doravirine (PIFELTRO)", "drugMoa": "NNRTI", "experience": "0.5 years; advisory boards and summaries", "previousAgency": "PRECISION AQ"}, {"diseaseState": "Virology (HIV)", "company": "Merck", "drugName": "doravirine/lamivudine/tenofovir (DELSTRIGO)", "drugMoa": "antiretroviral", "experience": "0.5 years; advisory boards and summaries", "previousAgency": "PRECISION AQ"}, {"diseaseState": "Hemoglobinopathies (SCD and TDT)", "company": "Vertex", "drugName": "exagamglogene autotemcel (CASGEVY)", "drugMoa": "gene therapy", "experience": "0.5 years; user manuals, conversation guides, learning decks", "previousAgency": "PRECISION AQ"}, {"diseaseState": "RSV", "company": "Pfizer", "drugName": "RSV vaccine (ABRYSVO)", "drugMoa": "vaccine", "experience": "0.5 years; decks", "previousAgency": "PRECISION AQ"}, {"diseaseState": "COVID-19", "company": "Pfizer-BioNTech", "drugName": "COVID-19 vaccine (COMIRNATY)", "drugMoa": "vaccine", "experience": "0.5 years; decks", "previousAgency": "PRECISION AQ"}, {"diseaseState": "RSV and hMPV", "company": "AstraZeneca/Icosavax", "drugName": "IVX-A12", "drugMoa": "VLP vaccine", "experience": "0.5 years; decks", "previousAgency": "PRECISION AQ"}, {"diseaseState": "Sophie Bolick", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Irritable bowel syndrome with diarrhea, travelers diarrhea", "company": "Salix Pharmaceuticals", "drugName": "Rifaximin", "drugMoa": "nonabsorbable antibiotic", "experience": "13 years; manuscripts, abstracts, posters, oral presentations, sales training materials, advisory boards (slides, summaries, on-site coverage), conference coverage", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Irritable bowel syndrome with constipation", "company": "Salix Pharmaceuticals (not Ardelyx)", "drugName": "Plecanatide", "drugMoa": "guanylate cyclase C-agonist", "experience": "~3 years; manuscripts, abstracts, posters", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Ulcerative colitis", "company": "Salix Pharmaceuticals", "drugName": "Budesonide rectal foam (Uceris); budesonide MMX (oral budesonide)", "drugMoa": "glucocorticosteroid", "experience": "2-3 years; manuscripts, abstracts, posters", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Ulcerative colitis", "company": "Salix Pharmaceuticals", "drugName": "Budesonide MMX (oral budesonide)", "drugMoa": "glucocorticosteroid", "experience": "2-3 years; manuscripts, abstracts, posters", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Fecal incontinence", "company": "now Palette Life Sciences Inc. (my experience was when this was a Salix Pharmaceuticals product)", "drugName": "Nonanimal stabilized hyaluronic acid (NASHA)/dextranomer (Dx) injection", "drugMoa": "Injectable bulking agent (anal canal)", "experience": "~2 years; manuscripts", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Chemotherapy-induced nausea and vomiting", "company": "Benuvia", "drugName": "Dronabinol", "drugMoa": "Cannabinoid", "experience": "1-2 years; manuscripts", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Hepatic encephalopathy", "company": "Bausch", "drugName": "Rifaximin", "drugMoa": "nonabsorbable antibiotic", "experience": "13 years; manuscripts, abstracts, posters, oral presentations, AMCP dossier update, sales training materials, advisory boards (slides, summaries, on-site coverage), conference coverage", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Colonoscopy (purgatives)", "company": "Salix Pharmaceuticals", "drugName": "MoviPrep", "drugMoa": "bowel prep", "experience": "3-4 years; abstracts, posters", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Colonoscopy (purgatives)", "company": "Salix Pharmaceuticals", "drugName": "Plenvu", "drugMoa": "bowel prep", "experience": "3-4 years; abstracts, posters", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Opioid-induced constipation", "company": "Salix Pharmaceuticals", "drugName": "Methylnaltrexone (Relistor)", "drugMoa": "mu-opoioid receptor antagonist", "experience": "5 years; manuscripts, abstracts, posters", "previousAgency": "MedThink SciCom; Synchrony Medical Communications"}, {"diseaseState": "Oncology", "company": "Amgen", "drugName": "Talimogene laherparepvec (T-VEC; IMLYGIC)", "drugMoa": "Immunotherapy", "experience": "0.5 year; Oral presentation", "previousAgency": "MedThink SciCom"}, {"diseaseState": "Colorectal cancer screening", "company": "Exact Sciences", "drugName": "Cologuard", "drugMoa": "CRC markers in stool", "experience": "0.25 year; Manuscript", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Allergy/anaphylaxis", "company": "ARS Pharma", "drugName": "Epinephrine injection", "drugMoa": "Epinephrine", "experience": "0.5-1 year; Manuscripts", "previousAgency": "MedThink SciCom"}, {"diseaseState": "Hereditary angioedema", "company": "Salix Phameceuticals", "drugName": "Ruconest", "drugMoa": "C1 esterase inhibitor", "experience": "~4-5 years; Manuscripts, abstracts, posters, oral presentations", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Ophthalmology (dry eye disease)", "company": "Novartis", "drugName": "Lifitegrast ophthalmic solution (Xiidra)", "drugMoa": "LFA-1 inhibitor", "experience": "1 year; Manuscripts, abstracts, posters", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Rare disease (primary periodic paralyses)", "company": "Sun", "drugName": "Dichlorphenamide", "drugMoa": "Carbonic anhydrase inhibitor", "experience": "1 year; Manuscripts", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Chronic pain", "company": "Elan", "drugName": "Intrathecal ziconotide", "drugMoa": "Analgesic", "experience": "1 year; Slides", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Diabetes", "company": "VeroScience/S2 Therapeutics", "drugName": "Bromocriptine (Cycloset)", "drugMoa": "Dopamine receptor agonist", "experience": "0.5 year; Manuscript", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Aesthetics (cellulite)", "company": "", "drugName": "Collagenase clostridium histolyticum-aaes (CCH-aaes) injection (Qwo - no longer marketed)", "drugMoa": "Enzymatic disruption of fibrous bands", "experience": "~2 years; Manuscripts, abstracts, oral presentations", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Dupuytren contracture (hand myofibroplastic disease)", "company": "BioSpecifics", "drugName": "Collagenase clostridium histolyticum (CCH) injection (Xiaflex)", "drugMoa": "Enzymatic disruption of collagen cord", "experience": "1-2 years; Manuscripts, training slide decks, MSL slide decks", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Peyronie's disease (penile deformity)", "company": "BioSpecifics", "drugName": "CCH injection (Xiaflex; enzymatic disruption of Peyronie's plaque)", "drugMoa": "Enyzmatic disruption of Peyronie's plaque", "experience": "1-2 years; Manuscripts, training slide decks, MSL slide decks", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Central precocious puberty", "company": "Endo", "drugName": "Histrelin subcutaneous implant (Supprelin)", "drugMoa": "Gonadotropin releasing hormone", "experience": "0.5 years; Training slide deck", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Opioid use disorder", "company": "Indivior", "drugName": "Buprenorphine extended release injection", "drugMoa": "Partial mu-opioid receptor agonist and kappa-opioid receptor antagonist", "experience": "1.5 years; Manuscript", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Opioid dependence", "company": "Braeburn", "drugName": "Buprenorphine and naloxone sublingual film", "drugMoa": "Partial opioid agonist (buprenorphine) and opioid antagonist (naloxone)", "experience": "~2 years; AMCP dossier updates", "previousAgency": "Synchrony Medical Communications"}, {"diseaseState": "Sophia Nies", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Oncology", "company": "Alphanumeric/Johnson & Johnson", "drugName": "niraparib/abiraterone acetate (Akeega)", "drugMoa": "PARP inhibitor", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Neurology", "company": "Alphanumeric/Johnson & Johnson", "drugName": "methylphenidate HCl (Concerta)", "drugMoa": "CNS stimulant", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Infectious Diseases", "company": "Alphanumeric/Johnson & Johnson", "drugName": "rilpivirine (Edurant)", "drugMoa": "NNRTI", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Internal Med", "company": "Alphanumeric/Johnson & Johnson", "drugName": "pentosan polysulfate sodium (Elmiron)", "drugMoa": "LMWH-like compound", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Immunology", "company": "Alphanumeric/Johnson & Johnson", "drugName": "Infliximab (Remicade)", "drugMoa": "TNF blocker", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Pulmonary Arterial Hypertension", "company": "Alphanumeric/Johnson & Johnson", "drugName": "macitentan (Opsumit)", "drugMoa": "ERA", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Cardiovascular", "company": "Alphanumeric/Johnson & Johnson", "drugName": "rivaroxaban (Xarelto)", "drugMoa": "DOAC", "experience": "Med Info Contact Center Support", "previousAgency": ""}, {"diseaseState": "Ann Stillman", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Diabetes", "company": "Novo Nordisk", "drugName": "Victoza, Rybelsus, Ozempic", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Obesity", "company": "Novo Nordisk", "drugName": "Wegovy, Saxenda", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Growth Hormone Deficiency", "company": "Novo Nordisk", "drugName": "Norditropin, Sogroya", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "NASH/MASH", "company": "Novo Nordisk", "drugName": "", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Rare Renal Disorders", "company": "Novo Nordisk", "drugName": "", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Hemophilia", "company": "Novo Nordisk", "drugName": "NovoSeven, NovoEight, Alhemo, Esperoct, Concizumab", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Acute Myocardial Infarction", "company": "Novo Nordisk", "drugName": "Ziltivekimab", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Sickle Cell Disease", "company": "Novo Nordisk", "drugName": "", "drugMoa": "", "experience": "3 years", "previousAgency": ""}, {"diseaseState": "Acromegaly", "company": "Amryt Pharma", "drugName": "Mycapssa", "drugMoa": "", "experience": "2 years", "previousAgency": ""}, {"diseaseState": "Shannon Daugherty", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "HemeOnc", "company": "Gilead", "drugName": "Magrolimab", "drugMoa": "", "experience": "1 yr", "previousAgency": "Ashfield MedComms"}, {"diseaseState": "Jen Kurdziel", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Hemophilia", "company": "Bayer", "drugName": "kogenate, kovaltry", "drugMoa": "", "experience": "5 years", "previousAgency": "CHC"}, {"diseaseState": "Pain/Neurology", "company": "Endo", "drugName": "opana, depodur", "drugMoa": "", "experience": "5 years", "previousAgency": "CHC/ICON"}, {"diseaseState": "Immunology", "company": "BMS", "drugName": "SOTYKTU (deucravacitinib)", "drugMoa": "", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Various", "company": "Johnson & Johnson", "drugName": "", "drugMoa": "", "experience": "2 years", "previousAgency": "Cello Health"}, {"diseaseState": "Oncology", "company": "Johnson & Johnson", "drugName": "esketamine", "drugMoa": "", "experience": "2 years", "previousAgency": "Cello Health"}, {"diseaseState": "Gene Therapy", "company": "Spark Therapeutics", "drugName": "", "drugMoa": "", "experience": "1 year", "previousAgency": "Cello Health"}, {"diseaseState": "Mike Morren", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Atopic dermatitis/vitiligo", "company": "Incyte", "drugName": "ruxolitinib cream (Opzelura)", "drugMoa": "JAK1/JAK2 inhibitor", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Hidradenitis suppurativa/vitiligo", "company": "Incyte", "drugName": "povorcitinib", "drugMoa": "JAK1 inhibitor", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Solar lentigines", "company": "Galderma", "drugName": "mequinol/tretinoin", "drugMoa": "depigmenting agent", "experience": "0.5 year", "previousAgency": "Cardinal Health"}, {"diseaseState": "Facial melasma", "company": "Galderma", "drugName": "flucinolone/hydrocholoroquine/tretinoin", "drugMoa": "antiinflammatory/depigmenting agent", "experience": "0.5 year", "previousAgency": "Cardinal Health"}, {"diseaseState": "Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis", "company": "Amgen", "drugName": "avacopan (Tavneos)", "drugMoa": "complement 5a receptor antagonist", "experience": "0.5 year", "previousAgency": "Open Health"}, {"diseaseState": "Acute hepatic porphyria", "company": "Alnylam", "drugName": "givosiran (Givlaari)", "drugMoa": "small interfering RNA", "experience": "3 years", "previousAgency": "Open Health"}, {"diseaseState": "Hepatorenal syndrome type 1", "company": "Ikaria/Mallinckrodt", "drugName": "terlipressin (Lucassin)", "drugMoa": "vasopressin receptor agonist", "experience": "2 years", "previousAgency": "Cardinal Health"}, {"diseaseState": "Primary hyperoxaluria type 1", "company": "Alnylam", "drugName": "lumasiran (Oxlumo)", "drugMoa": "small interfering RNA", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Obstructive sleep apnea/narcolepsy", "company": "Axsome", "drugName": "solriamfetol (Sunosi)", "drugMoa": "dopamine and norepinephrine reuptake inhibitor", "experience": "1 year", "previousAgency": "Open Health"}, {"diseaseState": "Hypoxic respiratory failure", "company": "Ikaria", "drugName": "inhaled nitric oxide (INOmax)", "drugMoa": "vasodilator", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Asthma", "company": "Novartis", "drugName": "indacaterol/glycopyrronium (Ultibro Breezehaler)", "drugMoa": "bronchodilator", "experience": "1 year", "previousAgency": "Cardinal Health"}, {"diseaseState": "Respiratory distress syndrome", "company": "Discovery Labs", "drugName": "lucinactant (Surfaxin)", "drugMoa": "pulmonary surfactant", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Asthma", "company": "Schering/Merck", "drugName": "mometasone duroate (Asmanex)", "drugMoa": "antiinflammatory", "experience": "1 year", "previousAgency": "Open Health"}, {"diseaseState": "Paroxysmal nocturnal hemoglobinuria", "company": "Alexion", "drugName": "eculizumab (Soliris)", "drugMoa": "complement inhibitor", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Paroxysmal nocturnal hemoglobinuria", "company": "Alexion", "drugName": "ravulizumab-cwvz (Ultomiris)", "drugMoa": "complement inhibitor", "experience": "0.5 year", "previousAgency": "Open Health"}, {"diseaseState": "Hemophilia A", "company": "Pfizer", "drugName": "moroctocog alfa", "drugMoa": "coagulation factor VIII", "experience": "1 year", "previousAgency": "Open Health"}, {"diseaseState": "Hemophilia A", "company": "Pfizer", "drugName": "giroctocogene fitelparvovec", "drugMoa": "adeno-associated virus-based gene therapy", "experience": "0.5 year", "previousAgency": "Open Health"}, {"diseaseState": "Hemophilia B", "company": "Pfizer", "drugName": "fidanacogen elaparvovec (Beqvez)", "drugMoa": "adeno-associated virus-based gene therapy", "experience": "1 year", "previousAgency": "Open Health"}, {"diseaseState": "Hemophilia B", "company": "Pfizer", "drugName": "nonacog alfa (Benefix)", "drugMoa": "coagulation factor IX", "experience": "1 year", "previousAgency": "Open Health"}, {"diseaseState": "Hemophilia A and B", "company": "Pfizer", "drugName": "marstacimab-hncq (Hympavzi)", "drugMoa": "tissue factor pathway inhibitor", "experience": "0.5 year", "previousAgency": "Open Health"}, {"diseaseState": "Anemia", "company": "Amgen", "drugName": "darbepoetin alfa (Aranaesp)", "drugMoa": "erythropoiesis-stimulating agent", "experience": "2 years", "previousAgency": "Cardinal Health"}, {"diseaseState": "Anemia", "company": "Ortho Biotech", "drugName": "epoeting alfa (Procrit)", "drugMoa": "erythropoiesis-stimulating agent", "experience": "2 years", "previousAgency": "Cardinal Health"}, {"diseaseState": "Thrombosis", "company": "Pfizer", "drugName": "dalteparin (Fragmin)", "drugMoa": "antithrombotic", "experience": "2 years", "previousAgency": "Cardinal Health"}, {"diseaseState": "lysosomal acid lipase deficiency", "company": "Alexion/Synageva", "drugName": "sebelipase alfa (Kanuma)", "drugMoa": "lysosomal ezyme", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "exocrine pancreatic insufficiency", "company": "Euran/Aptalis", "drugName": "pancrelipase (Zenpep)", "drugMoa": "pancreatic enzymes", "experience": "2 years", "previousAgency": "Cardinal Health"}, {"diseaseState": "postsurgical pain", "company": "Pacira", "drugName": "bupivacaine liposomal injection (Exparel)", "drugMoa": "local anesthetic", "experience": "3 years", "previousAgency": "Open Health"}, {"diseaseState": "Pain", "company": "Cephalon/Teva", "drugName": "fentanyl buccal tablets (Fentora)", "drugMoa": "opioid", "experience": "3 years", "previousAgency": "Open Health"}, {"diseaseState": "Pain", "company": "Alpharma", "drugName": "morphine sulfate ER (Kadian)", "drugMoa": "opioid", "experience": "2 years", "previousAgency": "Embryon/Genesis"}, {"diseaseState": "Pain", "company": "Endo", "drugName": "lidocaine patch (Lidoderm)", "drugMoa": "local anesthetic", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Pain", "company": "Endo", "drugName": "diclofenac sodium gel (Voltaren Gel)", "drugMoa": "NSAID", "experience": "1 year", "previousAgency": "Open Health"}, {"diseaseState": "Muscle spasm", "company": "Cephalon/Teva", "drugName": "cyclobenzaprine modified release (Amrix)", "drugMoa": "muscle relaxant", "experience": "3 years", "previousAgency": "Open Health"}, {"diseaseState": "Epilepsy", "company": "Aquestive", "drugName": "diazepam buccal film (Livervant)", "drugMoa": "benzodiazepine/GABA agonist", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Alzheimer's dementia / Parkinson's dementia", "company": "Novartis", "drugName": "rivastigmine transdermal patch (Exelon patch)", "drugMoa": "acetylcholinesterase inhibitor", "experience": "3 years", "previousAgency": "Open Health"}, {"diseaseState": "surgical reconstruction", "company": "LifeCell", "drugName": "non-crosslinked human dermal matrix (AlloDerm)", "drugMoa": "", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "surgical reconstruction", "company": "LifeCell", "drugName": "non-crosslinked acellular porcine matrix (Strattice)", "drugMoa": "", "experience": "2 years", "previousAgency": "Open Health"}, {"diseaseState": "Amanda Hall", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Endometrial cancer", "company": "GSK", "drugName": "dostarlimab (Jemperli)", "drugMoa": "PD-1 inhibitor", "experience": "1 year (MSL decks, congress decks, data launch training materials, SCP, brochure)", "previousAgency": "MediStrava/Apothecom"}, {"diseaseState": "Prostate cancer", "company": "JnJ", "drugName": "apalutamide (Erleada)", "drugMoa": "ARPI", "experience": "1 year (SCP update, congress decks)", "previousAgency": "MediStrava/Apothecom"}, {"diseaseState": "Prostate cancer", "company": "JnJ", "drugName": "niraparib (Zejula)", "drugMoa": "PARPi", "experience": "1 year (phase 3 final analysis PRO manuscript, congress decks)", "previousAgency": "MediStrava/Apothecom"}, {"diseaseState": "Prostate cancer", "company": "JnJ", "drugName": "h11b6", "drugMoa": "Radiolabeled anti-hK2 mAb", "experience": "1 year (Phase 0 manuscript)", "previousAgency": "MediStrava/Apothecom"}, {"diseaseState": "Bladder cancer", "company": "JnJ", "drugName": "TAR-200", "drugMoa": "Drug delivery system (gemcitabine)", "experience": "1 year (SCP update, congress decks)", "previousAgency": "MediStrava/Apothecom"}, {"diseaseState": "Endometrial cancer and ovarian cancer", "company": "Genmab", "drugName": "Rinatabart sesutecan (Rina-S)", "drugMoa": "ADC against FR\u03b1", "experience": "0.5 year (SCP for EC and OC)", "previousAgency": "MediStrava/Apothecom"}, {"diseaseState": "Major depressive disorder / pospartum disorder", "company": "Sage", "drugName": "Zuranalone", "drugMoa": "GABA-A", "experience": "1 year (MSL education decks for MDD and PPD, advisory boards)", "previousAgency": "sixsense strategy group"}, {"diseaseState": "ADA-SCID", "company": "Chiesi", "drugName": "elapegademase-lvlr (Revcovi)", "drugMoa": "Recombinant protein therapy (rADA)", "experience": "1 year (Digital training program ARTICULATE, advisory boards, standard response letters)", "previousAgency": "sixsense strategy group"}, {"diseaseState": "CLN5 Batten Disease", "company": "Neurogene", "drugName": "NGN-101", "drugMoa": "Gene therapy", "experience": "1 year (MSL decks, abstracts, posters, advisory boards)", "previousAgency": "sixsense strategy group"}, {"diseaseState": "Dan Jackson", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "ADHD", "company": "Otsuka Pharmaceuticals", "drugName": "Centanafadine", "drugMoa": "Serotonin 1A and dopamine D2 agonism", "experience": "Ad boards, Medical education and MSL decks", "previousAgency": "Citrus"}, {"diseaseState": "Agitation in alzheimers dementia", "company": "Otsuka Pharmaceuticals", "drugName": "Brexpiprazole (Rexulti)", "drugMoa": "Serotonin 1A and dopamine D2 agonism", "experience": "Ad boards, Medical education and MSL decks", "previousAgency": "Citrus"}, {"diseaseState": "Agitation in alzheimers dementia", "company": "Otsuka Pharmaceuticals", "drugName": "Agitation screening tool", "drugMoa": "PRO", "experience": "Publications and congress materials", "previousAgency": ""}, {"diseaseState": "Alzheimers disease psychosis", "company": "Acadia", "drugName": "Pimavanserin, ACP-204", "drugMoa": "serotonin 2a inverse agonist/antagonist", "experience": "Congress, publications, gap analyses, pub and tactical planning; KOL interviews", "previousAgency": "Citrus"}, {"diseaseState": "Alzheimers's dementia", "company": "Biogen", "drugName": "Lecanemab (Leqembi)", "drugMoa": "A-beta", "experience": "Market access and competitive intelligence", "previousAgency": "Citrus"}, {"diseaseState": "Asthma", "company": "AstraZeneca", "drugName": "Benralizumab (Fasenra), fluticasone/umeclidinium/vilanterol (Trelegy), budesonide/formoterol (symbicort); ICS/LABA/LAMA", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Medergy, Citrus"}, {"diseaseState": "Asthma", "company": "AstraZeneca", "drugName": "ReferID/Asthma Optimizer", "drugMoa": "PRO", "experience": "Congress, publications, steering committee", "previousAgency": "Citrus"}, {"diseaseState": "Asthma", "company": "AstraZeneca", "drugName": "AIRQ Asthma control tool", "drugMoa": "PRO", "experience": "Congress and publications", "previousAgency": "Medergy"}, {"diseaseState": "Asthma/COPD", "company": "Apogee therapeutics", "drugName": "APG777", "drugMoa": "IL-13", "experience": "KOL identification", "previousAgency": ""}, {"diseaseState": "Atopic dermatiis", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Atopic dermatitis", "company": "Apogee therapeutics", "drugName": "APG777", "drugMoa": "IL-13", "experience": "KOL identification", "previousAgency": ""}, {"diseaseState": "Bullous pemphigoid", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Cardiac arrhythmia/PSVT", "company": "Milestone Pharmaceuticals", "drugName": "Etripamil (Cardamyst)", "drugMoa": "Ca 2+ channel blocker", "experience": "", "previousAgency": "Citrus"}, {"diseaseState": "Chronic migraine", "company": "Teva", "drugName": "fremanezumab (Ajovy)", "drugMoa": "CGRP-inhibition", "experience": "Congress and publications", "previousAgency": "Medergy"}, {"diseaseState": "Chronic spontaneous urticaria", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Connective tissue disorders", "company": "Vital Proteins", "drugName": "Collagen and gelatin peptides/hydrolysates", "drugMoa": "Nutritional supplement", "experience": "", "previousAgency": "Freelance"}, {"diseaseState": "COPD", "company": "AstraZeneca", "drugName": "Benralizumab (Fasenra), fluticasone/umeclidinium/vilanterol (Trelegy), budesonide/formoterol (symbicort); ensifentrine (Ohtuvayre); roflumilast (Daliresp); ICS/LABA/LAMA", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Medergy, Citrus"}, {"diseaseState": "Eosinophilic esophagitis/duodenitis (EoE)", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Eosinophilic gastritis/gastroenteritis (EG/EGE)", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Eosinophilic granulomatosis with polyangitis (EGPA)", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Glioblastoma", "company": "Imvax", "drugName": "IGV-001", "drugMoa": "IGF type-1 antisense oligonucleotide", "experience": "", "previousAgency": ""}, {"diseaseState": "Gut health", "company": "Vital Proteins", "drugName": "Collagen and gelatin peptides/hydrolysates", "drugMoa": "Nutritional supplement", "experience": "", "previousAgency": "Freelance"}, {"diseaseState": "HIV", "company": "Janssen", "drugName": "D/C/F/TAF", "drugMoa": "darunavir, cobicistat, emtricitabine, tenofavir alafenamide", "experience": "Congress, publications, steering committee, ad board", "previousAgency": "Medergy"}, {"diseaseState": "Hypereosinophilic syndrome (HES)", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Infantile spasms", "company": "Mallinckrdot Pharmaceuticals", "drugName": "Repository corticotropin injection (Acthar gel)", "drugMoa": "", "experience": "Publications and steering committee support", "previousAgency": "Citrus"}, {"diseaseState": "MDS", "company": "Otsuka Pharmaceuticals", "drugName": "Brexpiprazole (Rexulti)", "drugMoa": "Serotonin 1A and dopamine D2 agonism", "experience": "Ad boards, Medical education and MSL decks", "previousAgency": "Citrus"}, {"diseaseState": "Multiple myeloma", "company": "J&J", "drugName": "Daratumumab (Darzalex)", "drugMoa": "anti-CD38", "experience": "Publications", "previousAgency": "Medergy"}, {"diseaseState": "Multiple sclerosis", "company": "Mallinckrdot Pharmaceuticals", "drugName": "Repository corticotropin injection (Acthar gel)", "drugMoa": "", "experience": "Publications and steering committee support", "previousAgency": "Citrus"}, {"diseaseState": "Multiple sclerosis", "company": "EMD serono", "drugName": "Cladribine (Mavenclad), interferon beta 1a(rebif)", "drugMoa": "Purine antimetabolite; interferon", "experience": "Competitive intelligence", "previousAgency": "Medergy"}, {"diseaseState": "Nasal polyps/chronic rhinosinusitis", "company": "AstraZeneca", "drugName": "Benralizumab", "drugMoa": "Eosinophil depletion via ADCC at IL-5 receptor alpha; PDE3/PDE4 dual inhibitor", "experience": "Congress, publications, steering committee, ad board, interactive virtual workshop, competitive intelligence, gap analysis, pub planning and tactics, lexicons", "previousAgency": "Citrus"}, {"diseaseState": "Neonatal pulmonary hypertension", "company": "Mallinckrdot Pharmaceuticals", "drugName": "Inhaled nitric oxide(INOmax)", "drugMoa": "", "experience": "Publications and steering committee support", "previousAgency": "Citrus"}, {"diseaseState": "Non-muscle invasive bladder cancer", "company": "Ferring Pharmaceuticals", "drugName": "nadaofaragene firadenovec (Adstiladrin)", "drugMoa": "", "experience": "Competitive intelligence", "previousAgency": "Citrus"}, {"diseaseState": "Opiod use disorder/chronic pain", "company": "Collegium Pharmaceuticals", "drugName": "Buphrenorphine buccal film", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Osteoarthritis", "company": "Vital Proteins", "drugName": "Collagen and gelatin peptides/hydrolysates", "drugMoa": "Nutritional supplement", "experience": "", "previousAgency": "Freelance"}, {"diseaseState": "Parkinson's disease psychosis", "company": "Acadia", "drugName": "Pimavanserin, ACP-204", "drugMoa": "serotonin 2a inverse agonist/antagonist", "experience": "", "previousAgency": "Citrus"}, {"diseaseState": "Rheumatic diseases", "company": "Mallinckrdot Pharmaceuticals", "drugName": "Repository corticotropin injection (Acthar gel)", "drugMoa": "", "experience": "Publications and steering committee support", "previousAgency": "Citrus"}, {"diseaseState": "Rheumatoid arthritis", "company": "Vital Proteins", "drugName": "Collagen and gelatin peptides/hydrolysates", "drugMoa": "Nutritional supplement", "experience": "", "previousAgency": "Freelance"}, {"diseaseState": "Systemic Lupus Erythromatosus/Lupus Nephritis", "company": "AstraZeneca and Mallinckrdot Pharmaceuticals", "drugName": "Anifrolumab (Saphnelo) and Repository corticotropin injection (Acthar gel)", "drugMoa": "", "experience": "", "previousAgency": "Medergy, Citrus"}, {"diseaseState": "Schizophrenia", "company": "Acadia", "drugName": "Pimavanserin", "drugMoa": "serotonin 2a inverse agonist/antagonist", "experience": "", "previousAgency": "Citrus"}, {"diseaseState": "Schizophrenia", "company": "Otsuka Pharmaceuticals", "drugName": "Brexpiprazole (Rexulti)", "drugMoa": "Serotonin 1A and dopamine D2 agonism", "experience": "Ad boards, Medical education and MSL decks", "previousAgency": "Citrus"}, {"diseaseState": "Sports nutrition", "company": "Vital Proteins", "drugName": "Collagen and gelatin peptides/hydrolysates", "drugMoa": "Nutritional supplement", "experience": "", "previousAgency": "Freelance"}, {"diseaseState": "Vascular closure/medical device", "company": "Cardiva medical", "drugName": "VASCADE venous vascular closure system (VVCS)", "drugMoa": "Collagen plug", "experience": "", "previousAgency": "Medergy"}, {"diseaseState": "Gregory Suess", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "ALK+ NSCLC", "company": "Genentech", "drugName": "ALECENSA (alectanib)", "drugMoa": "Tyrosine kinase inhibitor", "experience": "0.5 years (slide deck, med affairs materials)", "previousAgency": ""}, {"diseaseState": "Multiple cancers", "company": "Genentech", "drugName": "TECENTRIQ (atezolizumab)", "drugMoa": "PD-L1 inhibitor", "experience": "0.5 years (slide deck, med affairs materials)", "previousAgency": ""}, {"diseaseState": "Andrea Sutterer", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "IBS-D; IBS-C; OIC", "company": "Salix Pharmaceuticals", "drugName": "Rifaximin", "drugMoa": "nonabsorbable antibiotic", "experience": "3 years (manuscripts, abstracts, posters, oral presentations, AMCP dossier, advisory boards, conference coverage; pub planning)", "previousAgency": "MedThink SciCom"}, {"diseaseState": "Ulcerative colitis", "company": "Salix Pharmaceuticals", "drugName": "Budesonide rectal foam (Uceris); budesonide MMX (oral budesonide)", "drugMoa": "glucocorticosteroid", "experience": "3 years (manuscripts, abstracts, posters, oral presentations; pub planning)", "previousAgency": "MedThink SciCom"}, {"diseaseState": "Hepatic encephalopathy", "company": "Salix Pharmaceuticals", "drugName": "Rifaximin", "drugMoa": "nonabsorbable antibiotic", "experience": "3 years (manuscripts, abstracts, posters, oral presentations, AMCP dossier, sales training materials, advisory boards, conference coverage; pub planning)", "previousAgency": "MedThink SciCom"}, {"diseaseState": "Acute pain", "company": "QRxPharma Limited", "drugName": "MoxDuo (rejected by FDA; sold to Canadian company)", "drugMoa": "narcotic analgesic combination", "experience": ".5 yrs (commercial team/launch prep - consumer website; shelf talkers, advertisements)", "previousAgency": "inVentiv Communications"}, {"diseaseState": "GEJ", "company": "Eli Lilly", "drugName": "CYRAMZA", "drugMoa": "VEGFR2 antagonist", "experience": "3 years (manuscripts, abstracts, posters, oral presentations; pub planning)", "previousAgency": "ProEd Communication"}, {"diseaseState": "mNSCLC", "company": "Eli Lilly", "drugName": "CYRAMZA", "drugMoa": "VEGFR2 antagonist", "experience": "3 years (manuscripts, abstracts, posters, oral presentations; pub planning)", "previousAgency": "ProEd Communication"}, {"diseaseState": "Aesthetics (cellulite)", "company": "Endo", "drugName": "Collagenase clostridium histolyticum-aaes (CCH-aaes) injection (Qwo - no longer marketed)", "drugMoa": "Enzymatic disruption of fibrous bands", "experience": "3 years (manuscripts, abstracts, posters, oral presentations, conference coverage, SCP, lexicon, gap analysis, SLR, pub planning)", "previousAgency": "Synchrony"}, {"diseaseState": "Dupuytren contracture (hand myofibroplastic disease)", "company": "Endo", "drugName": "Collagenase clostridium histolyticum (CCH) injection (Xiaflex)", "drugMoa": "Enzymatic disruption of collagen cord", "experience": "3 years (manuscripts, abstracts, posters, oral presentations, Delphi Consensus, conference coverage, SLR, pub planning)", "previousAgency": "Synchrony"}, {"diseaseState": "Peyronie's disease (penile deformity)", "company": "Endo", "drugName": "CCH injection (Xiaflex; enzymatic disruption of Peyronie's plaque)", "drugMoa": "Enyzmatic disruption of Peyronie's plaque", "experience": "3 years (manuscripts, abstracts, posters, oral presentations, conference coverage, SLR, pub planning)", "previousAgency": "Synchrony"}, {"diseaseState": "Central precocious puberty", "company": "Endo", "drugName": "Histrelin subcutaneous implant (Supprelin)", "drugMoa": "Gonadotropin releasing hormone", "experience": "3 years (manuscripts, abstracts, posters, oral presentations)", "previousAgency": "Synchrony"}, {"diseaseState": "Digoxin toxicity", "company": "BTG Pharmaceuticals", "drugName": "DigiFab", "drugMoa": "", "experience": "2 yrs (Delphi Consensus)", "previousAgency": "Synchrony"}, {"diseaseState": "Stacy Gallogly", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Hepatocellular Carcinoma (HCC)", "company": "Eisai", "drugName": "LENVIMA", "drugMoa": "", "experience": "2.5 years", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Renal Cell Carcinoma (RCC)", "company": "Eisai", "drugName": "LENVIMA", "drugMoa": "", "experience": "2.5 years", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Differentiated Thyroid Cancer (DTC)", "company": "Eisai", "drugName": "LENVIMA", "drugMoa": "", "experience": "2.5 years", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Endometrial Cancer", "company": "Eisai", "drugName": "LENVIMA", "drugMoa": "", "experience": "2.5 years", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "metastatic Breast Cancer (mBC)", "company": "Eisai", "drugName": "HALAVEN", "drugMoa": "", "experience": "2.5 years", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Steven Merkel", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Non-valvular atrial fibrillation (NVAF)", "company": "Pfizer/BMS", "drugName": "Eliquis (apixaban)", "drugMoa": "Non-vitamin K antagonist oral anticoagulant (NOAC)", "experience": "7 years (real-world evidence reactive materials)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Venous thromboemolism (VTE)", "company": "Pfizer/BMS", "drugName": "Eliquis (apixaban)", "drugMoa": "Non-vitamin K antagonist oral anticoagulant (NOAC)", "experience": "7 years (real-world evidence reactive materials)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Neuromyelitis optica spectrum disorder (NMOSD)", "company": "Alexion", "drugName": "Soliris (eculizumab)", "drugMoa": "Anti-C5 monoclonal antibody (mAB)", "experience": "3.5 years (abstracts, posters, oral presenatations, manuscripts, video abstracts, graphical abstracts, plain language summaries)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Hypophosphatasia (HPP)", "company": "Alexion", "drugName": "Strensiq (asfotase alfa)", "drugMoa": "Enzyme replacement therapy (ERT) using recombinant, tissue-nonspecific alkaline phosphatase (TNSALP)", "experience": "4 years (abstracts, posters, manuscripts, plain language summaries)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Non-small cell lung carcinoma (NSCLC)", "company": "Merck", "drugName": "Keytruda (pembrolizumab)", "drugMoa": "Anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAB)", "experience": "2 years (clinical trial reactive materials)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Urothelial cell carcinoma (UCC; bladder cancer)", "company": "Astellas/Pfizer", "drugName": "PADCEV (enfortumab vedotin)", "drugMoa": "Antibody-drug conjugate (ADC) - anti-Nectin-4 monoclonal antibody (mAB) with a microtubule-disrupting agent called MMAE", "experience": "0.5 years (abstracts, posters, oral presentations, speaker briefs, plain language summaries)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Gastroesophogeal junction/gastric (GEJ/G) adenocarcinoma", "company": "Astellas", "drugName": "YYLOY (zolbetuximab)", "drugMoa": "Anti-claudin 18.2 monoclonal antibody (mAB)", "experience": "0.5 years (systematic literature review with PROSPERO submission)", "previousAgency": "Oxford PharmaGenesis"}, {"diseaseState": "Pulmonary hypertension/pulmonary arterial hypertension (PH/PAH)", "company": "Johnson & Johnson (Actelion Pharmaceuticals)", "drugName": "UPTRAVI (selexipag); Opsumit (macitentan)", "drugMoa": "Prostacyclin receptor agonist; endothelin receptor antagonist", "experience": "0.5 years (posters, oral presentations, manuscripts, publication plan, pub alerts, literature reviews)", "previousAgency": "Twist Medical"}, {"diseaseState": "Elizabeth Yannette", "company": "", "drugName": "", "drugMoa": "", "experience": "", "previousAgency": ""}, {"diseaseState": "Crohn's disease and ulcerative colitis", "company": "Takeda", "drugName": "ENTIVYO (vedolizumab)", "drugMoa": "", "experience": "3 years full pubs support", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "BCG unresponsive non-muscle invasive bladder cancer", "company": "Sesen Bio, now Carisma Therapeutics", "drugName": "Vicineum", "drugMoa": "", "experience": "Phase 3 publications support until FDA CRL", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "hypogonadism", "company": "Acerus", "drugName": "Natesto (testosterone) nasal gel", "drugMoa": "androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone", "experience": "3 years full pubs support", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "Hepatitis B", "company": "VBI Vaccines", "drugName": "PreHevbrio", "drugMoa": "", "experience": "1 year Phase 3 pubs/launch prep", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "malignant hyperthermia", "company": "Eagle Pharmaceuticals", "drugName": "Ryanodex (dantrolene sodium)", "drugMoa": "", "experience": "", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "supraventricular tachycardia", "company": "Eagle Pharmaceuticals", "drugName": "landiolol", "drugMoa": "", "experience": "Med Affairs decks and advisory board meeting", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "recurrent C. difficile infection (CDI)", "company": "Finch Therapeutics", "drugName": "CP101", "drugMoa": "", "experience": "SCP and Pub Plan", "previousAgency": "Cadent/Syneos"}, {"diseaseState": "sickle cell disease", "company": "Novartis", "drugName": "ADAKVEO (crizanlizumab-tmca)", "drugMoa": "", "experience": "2 years full pubs support", "previousAgency": "PHASE V, now part of VML"}, {"diseaseState": "hypoactive sexual desire disorder (HSDD)", "company": "AMAG", "drugName": "Vyleesi (bremelanotide)", "drugMoa": "", "experience": "2 years full pubs support and medical affairs tactics such a steering cmtes and ad boards", "previousAgency": "PHASE V, now part of VML"}, {"diseaseState": "RSV and Ebola", "company": "Novovax", "drugName": "protein-based nanoparticle and proprietary Matrix-M\u2122 adjuvant technology platform", "drugMoa": "", "experience": "2 years full pubs support, mostly focused on manuscripts", "previousAgency": "PHASE V, now part of VML"}], "academicExperience": [{"diseaseState": "Acute and chronic pain conditions (osteoarthritis, post-herpetic neuralgia, diabetic neuropathic pain, cancer pain, surgical pain, episodic and chronic migraine)", "drugName": "Erenumab (Amgen), Tanezumab (Pfizer),Pregabalin (Pfizer), Gabapentin (Pfizer), Abuse-deterrent opioids, Fentanyl, \u03b4-opioids (Pfizer) & (Cephalon), Coxibs (Pfizer)", "drugMoa": "anti-CGRP mAb, anti-NGF mAb, \u03b12\u03b4, \u03bc- and \u03b4-opioid receptors, COX inhibition", "experience": "1 year, 2 years, 5 years, 1 year, 1 year, 1 year, 1 year, 1 year"}, {"diseaseState": "Alzheimer's disease and agitation", "drugName": "Donepezil (Pfizer), AVP-786 (Avanir)", "drugMoa": "AChE inhibitor, unknown", "experience": "1 year, 1 year"}, {"diseaseState": "Atrial fibrillation/VTE/blood clotting", "drugName": "Dabigatran (BI), Idarucizumab (BI)", "drugMoa": "thrombin inhibitor, specific reversal agent", "experience": "2 years, 1 year"}, {"diseaseState": "Bipolar disorder", "drugName": "Olanzapine (Eli Lilly)", "drugMoa": "Atypical antipsychotic", "experience": "2 years"}, {"diseaseState": "Bone protection/osteoporosis", "drugName": "Denosumab (Amgen), Risedronate (Pfizer)", "drugMoa": "anti-RANKL mAb, bisphosphonate", "experience": "2 years, 1 year"}, {"diseaseState": "Depression/anxiety", "drugName": "Sertraline (Pfizer), Pregabalin (Pfizer)", "drugMoa": "SSRI, \u03b12\u03b4", "experience": "1 year, 5 years"}, {"diseaseState": "Diabetic nephropathy", "drugName": "Selonsertib (Gilead)", "drugMoa": "ASK1 inhibitor", "experience": "1 year"}, {"diseaseState": "Epilepsy", "drugName": "Brivaracetam (UCB), Pregabalin (Pfizer)", "drugMoa": "SV2A, \u03b12\u03b4", "experience": "1 year, 5 years"}, {"diseaseState": "Esophageal cancer", "drugName": "Nivolumab (BMS)", "drugMoa": "Immune checkpoint inhinitor", "experience": "1 year"}, {"diseaseState": "GERD, ulcers", "drugName": "Rabeprazole (Eisai, J&J)", "drugMoa": "Proton pump inhibitor", "experience": "2 years"}, {"diseaseState": "Hematologic cancers (ALL, AML, CLL, GVHD, NHL, DLBCL)", "drugName": "Blinatumomab (Amgen), Entospletinib (Gilead), Tirabrutinib (Gilead) , ibritumomab tiuxetan (Spectrum)", "drugMoa": "BiTE (CD3 x CD19), SYK inhibitor, BTK inhibitor, radiotherapy", "experience": "2 years"}, {"diseaseState": "Huntington\u2019s disease", "drugName": "Deutetrabenazine (Teva)", "drugMoa": "Monoamine depletion", "experience": "1 year"}, {"diseaseState": "Hypercholesterolemia", "drugName": "Atorvastatin (Pfizer), amlodipine/atorvastatin combination (Caduet) (Pfizer)", "drugMoa": "HMG-CoA reductase inhibitor, calcium channel blocker", "experience": "3 years, 1 year"}, {"diseaseState": "Hyperkalemia", "drugName": "Patiromer (Relypsa)", "drugMoa": "Potassium binder", "experience": "2 years"}, {"diseaseState": "Immune thrombocytopenia", "drugName": "Romiplostim (Amgen)", "drugMoa": "Thrombopoietin receptor, agonist", "experience": "1 year"}, {"diseaseState": "Menopause", "drugName": "Transdermal estradiol (Esprit)", "drugMoa": "Estrogen", "experience": "2 years"}, {"diseaseState": "Myelofibrosis", "drugName": "Momelotinib (Gilead)", "drugMoa": "JAK1/2 inhibitor", "experience": "2 years"}, {"diseaseState": "Prostate and lung cancers", "drugName": "Enzalutamide (Pfizer), Various early development products (Pfizer)", "drugMoa": "Anti-androgen, multiple", "experience": "1 year, 1 year"}, {"diseaseState": "Renal and hepatic cancers", "drugName": "Sorafenib (Onyx)", "drugMoa": "Multi-kinase inhibitor", "experience": "2 years, 2 years, 1 year, 1 year"}, {"diseaseState": "Rheumatoid arthritis", "drugName": "Filgotinib (Gilead), Lanraplenib (Gilead)", "drugMoa": "JAK1 inhibitor, SYK inhibitor", "experience": "3 years, 1 year"}, {"diseaseState": "Sleep/insomnia", "drugName": "Gabapentin (Pfizer), Eszopiclone (Sepracor)", "drugMoa": "\u03b12\u03b4 , GABAA receptor", "experience": "1 year, 1 year"}, {"diseaseState": "Type 2 diabetes", "drugName": "Empagliflozin (BI)", "drugMoa": "SGLT inhibitor", "experience": "1 year"}, {"diseaseState": "Patrick Little", "drugName": "", "drugMoa": "", "experience": ""}, {"diseaseState": "Chronic idiopathic constipation, C-IBS, opioid-induced constipation", "drugName": "Lubiprostone (Sucampo [Takeda])", "drugMoa": "Type 2 chloride channel (CIC-2) activator", "experience": "2 years"}, {"diseaseState": "UC, Crohn\u2019s/IBD", "drugName": "Humira (Abbvie)", "drugMoa": "Anti-TNF-alpha mAB", "experience": "2 years"}, {"diseaseState": "Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis", "drugName": "Humira (Abbvie)", "drugMoa": "Anti-TNF-alpha mAB", "experience": "6 months"}, {"diseaseState": "Neurogenic orthostatic hypotension", "drugName": "Northera (Lundbeck)", "drugMoa": "Norepinephrine prodrug", "experience": "4 years"}, {"diseaseState": "Migraine", "drugName": "Vyepti (Lundbeck)", "drugMoa": "Anti-CGRP mAb", "experience": "1.5 years"}, {"diseaseState": "Epilepsy (Lennox-Gastaut syndrome, Dravet  syndrome)", "drugName": "Onfi (Lundbeck)", "drugMoa": "GABAergic potentiation; benzodiazepine binding site", "experience": "1 year"}, {"diseaseState": "Epilepsy (broad spectrum)", "drugName": "Carnexiv (Lundbeck)", "drugMoa": "Voltage-sensitive sodium and calcium channel blocker", "experience": "1 year"}, {"diseaseState": "Tardive dyskinesia", "drugName": "Ingrezza (Neurocrine)", "drugMoa": "Vesicular monoamine transporter 2 inhibitor", "experience": "1 year"}, {"diseaseState": "Major depressive disorder", "drugName": "Vortioxetine (Lundbeck)", "drugMoa": "Monoamine reuptake inhibitor, 5-HT receptor agonist/antagonist/partial agonits", "experience": "1 year"}, {"diseaseState": "Treatment-resistant schiziophrenia", "drugName": "No specific product (Lundbeck)", "drugMoa": "", "experience": "2 years"}, {"diseaseState": "Acute and chronic pain", "drugName": "Arymo, Oxaydo, Sprix (Egalet)", "drugMoa": "Abuse-deterrent opiods (Arymo, Oxaydo), NSAID (Sprix)", "experience": "3 years"}, {"diseaseState": "Post-operative pain", "drugName": "Exparel (Pacira)", "drugMoa": "Bupivacaine (local anesthetic; liposomal release)", "experience": "6 months"}, {"diseaseState": "Chronic pain", "drugName": "Belbuca (buprenorphine buccal film, Endo)", "drugMoa": "Mixed opioid agonist/antagonist", "experience": "6 months"}, {"diseaseState": "Rheumatoid arthritis", "drugName": "Humira (Abbvie)", "drugMoa": "Anti-TNF-alpha mAB", "experience": "6 months"}, {"diseaseState": "Biosimilars", "drugName": "Amgen (position papers; not product specific)", "drugMoa": "", "experience": "1 year"}, {"diseaseState": "Precocious puberty", "drugName": "Supprelin LA (Endo)", "drugMoa": "Gonadotropin releasing hormone agonist", "experience": "6 months"}, {"diseaseState": "Endometriosis, uterine fibroids", "drugName": "Elagolix (AbbVie)", "drugMoa": "Gonadotropin releasing hormone antagonist", "experience": "6 months"}, {"diseaseState": "Gregory Bezkorovainy", "drugName": "", "drugMoa": "", "experience": ""}, {"diseaseState": "Diabetes", "drugName": "Victoza", "drugMoa": "GLP-1 agonist", "experience": "2 years"}, {"diseaseState": "Obesity", "drugName": "Victoza", "drugMoa": "GLP-1 agonist", "experience": "2 years"}, {"diseaseState": "Hypercholesterolemia", "drugName": "Lipitor", "drugMoa": "HMG-CoA reductase inhibitor", "experience": "2 years"}, {"diseaseState": "Hypertension", "drugName": "Norvasc", "drugMoa": "Ca channel blocker", "experience": "2 years"}, {"diseaseState": "Major depressive disorder", "drugName": "Zoloft", "drugMoa": "SSRI", "experience": "5 years"}, {"diseaseState": "Epilepsy", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years"}, {"diseaseState": "Neuropathic pain", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years"}, {"diseaseState": "Generalized anxiety disorder", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years"}, {"diseaseState": "Fibromyalgia", "drugName": "Lyrica", "drugMoa": "GABA analog", "experience": "6 years"}, {"diseaseState": "Schizophrenia", "drugName": "Geodon", "drugMoa": "Atypical antopsychotic", "experience": "6 months"}, {"diseaseState": "Alzheimer's Disease", "drugName": "Aricept", "drugMoa": "Central acetylcholinesterase inhibitor", "experience": "1.5 years"}, {"diseaseState": "Rheumatoid arthritis", "drugName": "Kevzara", "drugMoa": "IL-6 mAb", "experience": "1 years"}, {"diseaseState": "Overactive bladder", "drugName": "Vesicare", "drugMoa": "Bladder-specific antimuscarinic", "experience": "5 years"}, {"diseaseState": "Pulmonary hypertension", "drugName": "Adempas", "drugMoa": "Soluble guanylate cyclase stimulator", "experience": "4 years"}, {"diseaseState": "Osteoporosis", "drugName": "Tymlos", "drugMoa": "Parathyroid hormone-related protein analog", "experience": "2 years"}, {"diseaseState": "Allergic rhinitis", "drugName": "Nasonex", "drugMoa": "Corticosteroid", "experience": "2 years"}, {"diseaseState": "Allergic rhinitis", "drugName": "Claritin", "drugMoa": "Antihistamine", "experience": "2 years"}, {"diseaseState": "Allergic rhinitis", "drugName": "Grastek, Ragwitek", "drugMoa": "Oral immunotherapy", "experience": "2 years"}, {"diseaseState": "COPD", "drugName": "Dulera", "drugMoa": "Corticosteroid/LABA", "experience": "1 years"}, {"diseaseState": "Asthma", "drugName": "Asmanex; Dulera", "drugMoa": "Corticosteroid; corticosteroid/LABA", "experience": "2 years"}], "asdSdExperience": [{"person": "Gilead", "diseaseState": "chronic infection with hepatitis delta virus", "drugName": "Hepcludex (bulevirtide)", "drugMoa": "viral entry inhibitor", "experience": "conference presentations, full papers; strategy workshops"}, {"person": "Gilead", "diseaseState": "chronic infection with hepatitis C virus", "drugName": "Epclusa (sofosbuvir/velpatasvir)", "drugMoa": "NS5B/NS5A polymerase inhibitor", "experience": "conference presentations, full papers"}, {"person": "Gilead", "diseaseState": "chronic infection with hepatitis B virus", "drugName": "Vemlidy (tenofovir alafenamide); Viread (tenofovir disoproxil fumarate)", "drugMoa": "HBV replication inhibitors", "experience": "conference presentations, full papers"}, {"person": "Gilead", "diseaseState": "HIV infection", "drugName": "Sunlenca (lenacapavir)", "drugMoa": "capsid inhibitor", "experience": "full paper"}, {"person": "Gilead", "diseaseState": "rheumatoid arthritis", "drugName": "Jyseleca (filgotinib)", "drugMoa": "JAK-1 inhibitr", "experience": "conference presentations, full papers"}, {"person": "Gilead", "diseaseState": "hematologic oncology", "drugName": "multiple", "drugMoa": "multiple", "experience": "full papers for failed drugs"}, {"person": "Gilead", "diseaseState": "respiratory syncitial virus", "drugName": "presatovir", "drugMoa": "RSV fusion inhibitor", "experience": "full papers for failed drug"}, {"person": "Gilead", "diseaseState": "primary biliary cholangitis", "drugName": "Livdelzi (seladelpar)", "drugMoa": "PPAR-delta agonist", "experience": "SCP, abstracts, posters"}, {"person": "Travere", "diseaseState": "immunoglobulin A nephropathy", "drugName": "Filspari (sparsentan)", "drugMoa": "dual ET-1 and Ang II inhibitor", "experience": "ad bds, conference presentations"}, {"person": "Assembly", "diseaseState": "chronic infection with hepatitis B virus", "drugName": "vebicorvir", "drugMoa": "core inhibitor", "experience": "conference presentations, full papers"}, {"person": "Atea", "diseaseState": "COVID19 infection", "drugName": "AT-527", "drugMoa": "viral RNA polymerase inhibitor", "experience": "ad bds, conference presentations"}, {"person": "ArkBio", "diseaseState": "respiratory syncitial virus", "drugName": "ziresovir", "drugMoa": "RSV fusion (F) protein inhibitor", "experience": "2 full papers"}, {"person": "Createrna", "diseaseState": "paroxysmal nocturnal hemoglobinuria", "drugName": "MY008211A", "drugMoa": "complement factor B inhibitor", "experience": "abstract, poster"}, {"person": "Jane Kovalevich", "diseaseState": "Solid tumors", "drugName": "RP1, RP2, RP3", "drugMoa": "Oncolytic virus", "experience": "Manuscripts, abstracts, oral presentations, white papers"}, {"person": "Jane Kovalevich", "diseaseState": "COPD/asthma", "drugName": "Revefenacin", "drugMoa": "LAMA", "experience": "Manuscripts, posters"}, {"person": "Jane Kovalevich", "diseaseState": "Neurogenic orthostatic hypotension", "drugName": "Ampreloxetine", "drugMoa": "NE reuptake inhibitor", "experience": "Manuscripts, posters, oral presentation"}, {"person": "Jane Kovalevich", "diseaseState": "Ulcerative colitis/Crohn's disease", "drugName": "Izencitinib", "drugMoa": "JAK inhibitor", "experience": "Posters"}, {"person": "Jane Kovalevich", "diseaseState": "COVID-19", "drugName": "Nezulcitinib", "drugMoa": "JAK inhibitor", "experience": "Manuscript"}, {"person": "Jane Kovalevich", "diseaseState": "Lupus (SLE, LN, DLE)", "drugName": "Daxdilimab", "drugMoa": "ILT7 inhibitor", "experience": "SCPs"}, {"person": "Jane Kovalevich", "diseaseState": "Sjogren's", "drugName": "Dazodalibep", "drugMoa": "CD40L antagonist", "experience": "SCP, plain language conversion for market research"}, {"person": "Jane Kovalevich", "diseaseState": "Kidney transplant rejection", "drugName": "Dazodalibep", "drugMoa": "CD40L antagonist", "experience": "Oral presentation, manuscript"}, {"person": "Jane Kovalevich", "diseaseState": "Diffuse cutaneous systemic sclerosis", "drugName": "HZN-825", "drugMoa": "LPAR1 antagonist", "experience": "Oral presentation, manuscript"}, {"person": "Jane Kovalevich", "diseaseState": "Idiopathic pulmonary fibrosis", "drugName": "HZN-825", "drugMoa": "LPAR1 antagonist", "experience": "Oral presentation, manuscript"}, {"person": "Jane Kovalevich", "diseaseState": "IgG4-RD", "drugName": "UPLIZNA (inebilizumab)", "drugMoa": "CD19", "experience": "Review manuscripts, plain language conversion for market research"}, {"person": "Jane Kovalevich", "diseaseState": "HBV", "drugName": "Vebicorvir, ABI-3733, ABI-4334", "drugMoa": "HBV core inhibitor", "experience": "Manuscripts, abstracts, oral presentations"}, {"person": "Jane Kovalevich", "diseaseState": "HBV/HDV", "drugName": "Preclinical (multiple)", "drugMoa": "Entry inhibitor", "experience": "Abstracts, posters, oral presentations"}, {"person": "Jane Kovalevich", "diseaseState": "Hidradenitis suppurativa", "drugName": "Izokibep", "drugMoa": "IL-17 inhibitor", "experience": "Abstract, SCP, gap analysis (initiated)"}, {"person": "Jane Kovalevich", "diseaseState": "Psoriatic arthritis", "drugName": "Izokibep", "drugMoa": "IL-17 inhibitor", "experience": "Poster, oral presentation, SCP, gap analysis (initiated)"}, {"person": "Jane Kovalevich", "diseaseState": "Thyroid eye disease", "drugName": "Lonigutamab", "drugMoa": "Anti-IGF-1R mAb", "experience": "Abstracts, posters, oral presentations, manuscripts, SCP, gap analysis, congress handouts, publication planning"}, {"person": "Kathleen Pieper", "diseaseState": "Hemophilia A", "drugName": "Roctavian (valoctocogene roxaparvovec)", "drugMoa": "AAV5 gene therapy for FVIII replacement", "experience": "Manuscripts, presentations, posters, abstracts, competitor anaylsis (clinical, preclinical, HEOR, plain language)"}, {"person": "Kathleen Pieper", "diseaseState": "Hereditary angioedema types I and II", "drugName": "BMN 331", "drugMoa": "AAV5 gene therapy for C1-INH replacement", "experience": "Manuscripts, presentations, posters, abstracts, SCP (clinical and preclinical)"}, {"person": "Kathleen Pieper", "diseaseState": "Duchene muscular dystrophy", "drugName": "BMN 351", "drugMoa": "Antisense oligonucleotide targeting exon 51", "experience": "Manuscripts, presentations, posters, abstracts (preclinical), SCP"}, {"person": "Kathleen Pieper", "diseaseState": "MYBPC3-deficient hypertrophic cardiomyopathy", "drugName": "BMN 293", "drugMoa": "AAV gene therapy for MYBPC3 replacement", "experience": "Posters (preclinical), SCP"}, {"person": "Kathleen Pieper", "diseaseState": "PKU", "drugName": "Palynziq (pegvaliase)", "drugMoa": "Enzyme replacement therapy (pegylated derivative of phenylalanine ammonia-lyase)", "experience": "SCP"}, {"person": "Kathleen Pieper", "diseaseState": "Stroke prevention in AF, secondary prevention in VTE", "drugName": "Edoxaban", "drugMoa": "Factor Xa inhibitor", "experience": "Manusripts, abstracts, oral presentations, posters"}, {"person": "Kathleen Pieper", "diseaseState": "Plaque psoriasis", "drugName": "Tildrakizumab", "drugMoa": "IL-23 inhibitor", "experience": "Manuscripts, abstracts, oral presentations, posters"}, {"person": "Kathleen Pieper", "diseaseState": "Rheumatoid arthritis", "drugName": "Filgotinib", "drugMoa": "JAK inhibitor", "experience": "Manuscripts, abstracts, oral presentations, posters"}, {"person": "Kathleen Pieper", "diseaseState": "Sjogren's", "drugName": "Dazodalibep", "drugMoa": "CD40L antagonist", "experience": "SCP"}, {"person": "Kathleen Pieper", "diseaseState": "Knee osteoarthritis", "drugName": "MM-II", "drugMoa": "Intra-articular injection of multilamellar liposomes", "experience": "Manuscripts, abstracts, posters"}, {"person": "Kathleen Pieper", "diseaseState": "Achondroplasia, hypochondroplasia, idiopathic short stature", "drugName": "Voxzogo (vosoritide)", "drugMoa": "C-type natriuretic peptide analogue", "experience": "Poster"}, {"person": "Kathleen Pieper", "diseaseState": "Spinal muscular atrophy", "drugName": "Apitegromab", "drugMoa": "Latent myostatin inhibitor", "experience": "Abstract, posters, manuscripts, SCP, presentations"}, {"person": "Kathleen Pieper", "diseaseState": "Solid tumors resistant/refractive to PD1-inhibitors", "drugName": "Linavonkibart", "drugMoa": "TGFB-1 inhibitor", "experience": "Poster, manuscript"}, {"person": "Kathleen Pieper", "diseaseState": "Alpha-1 antitrypsin deficiency", "drugName": "BMN 349", "drugMoa": "Small molecule Z-AAT chaperone", "experience": "Posters, manuscripts, SCP"}, {"person": "Kathleen Pieper", "diseaseState": "Obesity", "drugName": "Contrave", "drugMoa": "Reward system regulator", "experience": "Manuscripts, advisory (editorial) board"}, {"person": "Lauren Hanlon", "diseaseState": "Gastrointestinal Stromal Tumor", "drugName": "Ripretinib (QINLOCK)", "drugMoa": "KIT/PDGFRA inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations, SCP, plain language summaries"}, {"person": "Lauren Hanlon", "diseaseState": "Tenosynovial Giant Cell Tumor", "drugName": "Vimseltinib", "drugMoa": "CSF1R inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations, SCP, plain language summaries, MSL training decks, MSL field materials, infographics, one-pagers"}, {"person": "Lauren Hanlon", "diseaseState": "RAS/RAF-mutant cancers", "drugName": "DCC-3116", "drugMoa": "ULK inhibitor (autophagy)", "experience": "Abstracts, posters, oral presentations, SCP, patient advocacy deck"}, {"person": "Lauren Hanlon", "diseaseState": "Gastrointestinal Stromal Tumor", "drugName": "DCC-3009", "drugMoa": "KIT/PDGFRA inhibitor", "experience": "Abstracts, posters, SCP"}, {"person": "Lauren Hanlon", "diseaseState": "Advanced Cancers with BRAF class II mutations", "drugName": "DCC-3084", "drugMoa": "BRAF/CRAF inhibitor", "experience": "Abstracts, posters, SCP"}, {"person": "Lauren Hanlon", "diseaseState": "Solid tumors", "drugName": "DP-9149", "drugMoa": "GCN2 kinase activator", "experience": "Posters"}, {"person": "Lauren Hanlon", "diseaseState": "Advanced Breast Cancer", "drugName": "Vepdegestrant", "drugMoa": "PROTAC estrogen receptor degrader", "experience": "Manuscripts, abstracts, posters, oral presentations, plain language summaries, SCP, MSL training decks, MSL field materials, infographics, interactive PDFs, MOA videos"}, {"person": "Lauren Hanlon", "diseaseState": "Metastatic Castration-Resistant Prostate Cancer", "drugName": "Bavdegalutamide", "drugMoa": "PROTAC androgen receptor degrader", "experience": "Manuscripts"}, {"person": "Lauren Hanlon", "diseaseState": "Non-Hodgkin Lymphoma", "drugName": "ARV-393", "drugMoa": "PROTAC BCL6 degrader", "experience": "Abstracts, posters, SCP, MSL field materials, infographics, interactive PDFs, MOA videos"}, {"person": "Lauren Hanlon", "diseaseState": "Duchenne Muscular Dystrophy", "drugName": "viltolarsen", "drugMoa": "Exon 53-skipping antisense oligonucleotide", "experience": "abstracts, posters, oral presentations, manuscripts, plain language conversion of slide decks, patient advocacy deck"}, {"person": "Lauren Hanlon", "diseaseState": "Duchenne Muscular Dystrophy", "drugName": "NS-089", "drugMoa": "Exon 44-skipping antisense oligonucleotide", "experience": "abstracts, oral presentations"}, {"person": "Lauren Hanlon", "diseaseState": "Duchenne Muscular Dystrophy", "drugName": "NS-050", "drugMoa": "Exon 50-skipping antisense oligonucleotide", "experience": "abstracts, posters"}, {"person": "Lauren Hanlon", "diseaseState": "Multiple Myeloma", "drugName": "CB-011", "drugMoa": "Engineered allogeneic CAR-T therapy", "experience": "Manuscript, SCP, Lexicon"}, {"person": "Lauren Hanlon", "diseaseState": "Non-Hodgkin Lymphoma", "drugName": "CB-010", "drugMoa": "Engineered allogeneic CAR-T therapy", "experience": "SCP, Lexicon"}, {"person": "Lauren Hanlon", "diseaseState": "Acute Myeloid Leukemia", "drugName": "CB-012", "drugMoa": "Engineered allogeneic CAR-T therapy", "experience": "SCP, Lexicon"}, {"person": "Lauren Hanlon", "diseaseState": "Ulcerative colitis", "drugName": "MORF-057", "drugMoa": "a4b7 inhibitor", "experience": "Poster"}, {"person": "Lauren Hanlon", "diseaseState": "Knee osteoarthritis", "drugName": "MM-II", "drugMoa": "Intra-articular injection of multilamellar liposomes", "experience": "Poster, oral presentation"}, {"person": "Lauren Hanlon", "diseaseState": "Stroke prevention in AF, secondary prevention in VTE", "drugName": "Edoxaban", "drugMoa": "Factor Xa inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations, gap analysis, ad boards"}, {"person": "Lauren Hanlon", "diseaseState": "Skin cancers, solid tumors, solid tumors after organ transplant", "drugName": "RP1, RP2, RP3", "drugMoa": "Oncolytic virus", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "Lauren Hanlon", "diseaseState": "Thrombosis prevention in patients with EKSD receiving hemodialysis", "drugName": "MK-2060", "drugMoa": "Factor XI/XIa inhibitor", "experience": "SCP"}, {"person": "Lauren Hanlon", "diseaseState": "HBV", "drugName": "Vebicorvir (ABI-H0731), ABI-2158, ABI-3733", "drugMoa": "HBV core inhibitor", "experience": "slide decks, posters"}, {"person": "Mike Morren", "diseaseState": "HDV infection", "drugName": "Bulevirtide (Hepcludex)", "drugMoa": "sodium taurocholate cotransporting polypeptide (NCTP) HBV/HDV entry receptor inhibitor", "experience": "abstracts, posters, oral presentations, manuscripts"}, {"person": "Mike Morren", "diseaseState": "HCV infection", "drugName": "sofosbuvir / velpatasvir (Epclusa)", "drugMoa": "HCV nucleotide analog NS5B polymerase inhibitor; direct-acting antiviral", "experience": "abstracts, posters, oral presentations, manuscripts"}, {"person": "Zehra Gundogan", "diseaseState": "Major depressive disorder", "drugName": "Zuranolone", "drugMoa": "PAM of GABA A receptors and NAS", "experience": "Manuscripts, posters, abstracts, slide decks"}, {"person": "Zehra Gundogan", "diseaseState": "Postpartum depression", "drugName": "Zuranolone; Brexanolone", "drugMoa": "PAM of GABA A receptors and NAS", "experience": "Manuscripts, posters, abstracts, slide decks"}, {"person": "Zehra Gundogan", "diseaseState": "Keratoconjunctivitis sicca", "drugName": "OTX-101", "drugMoa": "Calcineurin inhibitor, p38 and JNK inhibitor", "experience": "Manuscripts, dossier support"}, {"person": "Zehra Gundogan", "diseaseState": "Basal cell carcinoma", "drugName": "Sonidegib", "drugMoa": "Hedgehog inhibitor", "experience": "Manuscripts, abstracts, posters"}, {"person": "Zehra Gundogan", "diseaseState": "HPV16+ head and neck squamous cell carcinoma", "drugName": "HB-201, HB-202", "drugMoa": "CD8+ stimulation", "experience": "Abstracts, slide decks"}, {"person": "Zehra Gundogan", "diseaseState": "Prostate cancer", "drugName": "Abiraterone acetate", "drugMoa": "Androgen synthesis inhibitor", "experience": "Manuscripts"}, {"person": "Zehra Gundogan", "diseaseState": "Congenital ichthyosis", "drugName": "Isotretinoin", "drugMoa": "Retinoid", "experience": "Manuscripts, abstracts, oral presentations, posters"}, {"person": "Zehra Gundogan", "diseaseState": "Scleroderma", "drugName": "Sitaxentan", "drugMoa": "Selective ET-A receptor antagonist", "experience": "Manuscripts, abstracts"}, {"person": "Zehra Gundogan", "diseaseState": "PTSD", "drugName": "MDMA", "drugMoa": "Releaser and/or reuptake inhibitor of serotonin, dopamine, and norepinephrine", "experience": "Manuscript"}, {"person": "Francesca Hemingway", "diseaseState": "COPD/asthma", "drugName": "Revefenacin", "drugMoa": "LAMA", "experience": "Manuscripts, posters"}, {"person": "Francesca Hemingway", "diseaseState": "Neurogenic orthostatic hypotension", "drugName": "Ampreloxetine", "drugMoa": "NE reuptake inhibitor", "experience": "Manuscripts, posters"}, {"person": "Francesca Hemingway", "diseaseState": "HBV", "drugName": "Vebicorvir, ABI-3733, ABI-4334", "drugMoa": "HBV core inhibitor", "experience": "Manuscripts, posters"}, {"person": "Francesca Hemingway", "diseaseState": "HBV/HDV", "drugName": "ABI-6250", "drugMoa": "Entry inhibitor", "experience": "Manuscripts, posters"}, {"person": "Francesca Hemingway", "diseaseState": "Genital herpes", "drugName": "ABI-1179, ABI-5366", "drugMoa": "Helicase-Primase Inhibitor", "experience": "Abstracts, posters"}, {"person": "Francesca Hemingway", "diseaseState": "Gout", "drugName": "Pegloticase", "drugMoa": "Pegylated uricase enzyme", "experience": "Manuscripts, posters, slide decks"}, {"person": "Francesca Hemingway", "diseaseState": "Sjogren's disease", "drugName": "Dazodalibep, AMG329", "drugMoa": "CD40L antagonist, monoclonal antibody", "experience": "Manuscripts, posters, abstracts, slide decks, SCPs, lexicon, PLSPs"}, {"person": "Francesca Hemingway", "diseaseState": "SLE", "drugName": "Daxdilimab", "drugMoa": "Monoclonal antibody - immunoglobulin-like transcript 7", "experience": "Manuscripts, posters, abstracts, slide decks, SCPs"}, {"person": "Francesca Hemingway", "diseaseState": "Alopecia areata", "drugName": "Daxdilimab", "drugMoa": "Monoclonal antibody - immunoglobulin-like transcript 7", "experience": "Brief Communication"}, {"person": "Francesca Hemingway", "diseaseState": "IPF/PPF", "drugName": "Fipaxalparant", "drugMoa": "Negative allosteric modulator of LPAR1", "experience": "Manuscripts, slide decks, SCPs, 1-pagers"}, {"person": "Francesca Hemingway", "diseaseState": "IgG4-RD", "drugName": "Inebilizumab", "drugMoa": "Monoclonal antibody - CD19 B cells", "experience": "Manuscripts, MILs, PLSPs, Posters, Oral presentations, Slide decks, Brochure"}, {"person": "Francesca Hemingway", "diseaseState": "Myasthenias gravis", "drugName": "Inebilizumab", "drugMoa": "Monoclonal antibody - CD19 B cells", "experience": "Manuscripts, MILs, PLSPs, Posters, Oral presentations, Slide decks, Brochure"}, {"person": "Francesca Hemingway", "diseaseState": "NMOSD", "drugName": "Inebilizumab", "drugMoa": "Monoclonal antibody - CD19 B cells", "experience": "MILs"}, {"person": "Francesca Hemingway", "diseaseState": "Thyroid eye disease", "drugName": "Teprotumamab", "drugMoa": "Monoclonal antibody", "experience": "Posters, Manuscripts"}, {"person": "Francesca Hemingway", "diseaseState": "Lp(a) and ASCVD", "drugName": "Olpasiran", "drugMoa": "Small interfering RNA - Lp(a)", "experience": "Slide decks, SCP"}, {"person": "Francesca Hemingway", "diseaseState": "Hyperlipidemia", "drugName": "Evolocumab (Repatha)", "drugMoa": "Monoclonal antibody - proprotein convertase subtilisin/kexin type 9", "experience": "Manuscripts, posters, abstracts, slide decks, PLSPs, patient website articles"}, {"person": "Francesca Hemingway", "diseaseState": "Osteoporosis", "drugName": "Evenity (romosozumab-aqqg), Prolia (denosumab)", "drugMoa": "Monoclonal antibody", "experience": "Infographic, patient website"}, {"person": "Judy Phillips", "diseaseState": "HAP/VAP", "drugName": "telavancin", "drugMoa": "antibiotic (bactericidal lipoglycopeptide)", "experience": "Manuscripts, posters"}, {"person": "Judy Phillips", "diseaseState": "cSSSI", "drugName": "telavancin", "drugMoa": "antibiotic (bactericidal lipoglycopeptide)", "experience": "Manuscripts, posters"}, {"person": "Judy Phillips", "diseaseState": "Ulcerative colitis", "drugName": "izencitinib", "drugMoa": "JAK inhibitor", "experience": "Manuscripts, posters, competitive intelligence"}, {"person": "Judy Phillips", "diseaseState": "COVID-19", "drugName": "nezulcitinib", "drugMoa": "JAK inhibitor", "experience": "Manuscripts, abtracts, posters"}, {"person": "Judy Phillips", "diseaseState": "Asthma", "drugName": "TD-8236", "drugMoa": "JAK inhibitor", "experience": "Posters"}, {"person": "Judy Phillips", "diseaseState": "RSV infection", "drugName": "presatovir", "drugMoa": "antiviral (fusion inhibitor)", "experience": "Manuscripts"}, {"person": "Judy Phillips", "diseaseState": "Plaque psoriasis", "drugName": "tildrakizumab", "drugMoa": "anti-IL-23 p19 antibody", "experience": "Manuscripts, abstracts, posters, congress presentations, internal presentations, MSL slides, medical information letters, lexicon, publication planning, FAQ documents, AMCP dossier support, website content, gap analyses"}, {"person": "Judy Phillips", "diseaseState": "Psoriatic arthritis", "drugName": "tildrakizumab", "drugMoa": "anti-IL-23 p19 antibody", "experience": "Manuscripts, abstracts, posters, MSL slides, medical information letters"}, {"person": "Judy Phillips", "diseaseState": "Actinic keratosis", "drugName": "20% aminolevulinic acid solution (Levulan)", "drugMoa": "Photosensitizer", "experience": "Manuscripts, abstracts, posters, MSL slides, medical information letters, lexicon"}, {"person": "Judy Phillips", "diseaseState": "Acne vulgaris", "drugName": "clascoterone cream 1%", "drugMoa": "topical anti-androgen", "experience": "Manuscripts, abstracts, posters, MSL slides, medical information letters, lexicon, AMCP dossier support, gap analyses"}, {"person": "Judy Phillips", "diseaseState": "Acne vulgaris", "drugName": "lidose isotretinoin and micronized isotretinoin", "drugMoa": "retinoid", "experience": "Manuscripts, abstracts, posters, slide decks, gap analyses"}, {"person": "Judy Phillips", "diseaseState": "Alopecia areata", "drugName": "deuruxolitinib", "drugMoa": "JAK inhibitor", "experience": "Slide decks, medical information letters, publication planning"}, {"person": "Judy Phillips", "diseaseState": "Obesity/type 2 diabetes mellitus", "drugName": "utreglutide", "drugMoa": "glucagon-like peptide 1 receptor agonist", "experience": "Posters"}, {"person": "Judy Phillips", "diseaseState": "rheumatoid arthritis", "drugName": "filgotinib", "drugMoa": "JAK inhibitor", "experience": "Manuscripts, abstracts, posters"}, {"person": "Judy Phillips", "diseaseState": "Neurology rare disease (Alexander disease)", "drugName": "zilganersen", "drugMoa": "antisense oligonucleotide", "experience": "Scientific communication platform"}, {"person": "Judy Phillips", "diseaseState": "Neurology rare disease (prion disease)", "drugName": "ION717", "drugMoa": "antisense oligonucleotide", "experience": "Scientific communication platform"}, {"person": "Judy Phillips", "diseaseState": "Cardiometabolic rare disease (familial chylomicronemia syndrome)", "drugName": "olezarsen", "drugMoa": "antisense oligonucleotide", "experience": "Manuscripts, oral presentations"}, {"person": "Judy Phillips", "diseaseState": "Thromboembolic disease", "drugName": "edoxaban", "drugMoa": "direct Factor Xa inhibitor anticoagulant", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "Judy Phillips", "diseaseState": "mTOR-driven cancers", "drugName": "nab-sirolimus", "drugMoa": "mTOR inhibitor", "experience": "Abstracts, posters, gap analyses"}, {"person": "ASD", "diseaseState": "Alopecia areata", "drugName": "Deuruxolitinib", "drugMoa": "JAK inhibitor", "experience": "Dossiers (pre- and post-approval), manuscripts, medical information letters, abstracts, posters"}, {"person": "Ellie Manca", "diseaseState": "HIV", "drugName": "lenacapavir", "drugMoa": "antiretroviral, long-acting HIV capsid inhibitor", "experience": "Manuscript"}, {"person": "Ellie Manca", "diseaseState": "HBV and HDV", "drugName": "bulevirtide", "drugMoa": "antiviral, NTCP binding/inactivating", "experience": "Manuscripts, posters, abstracts, encores, gap analysis"}, {"person": "Ellie Manca", "diseaseState": "Schizophrenia", "drugName": "TV-46000", "drugMoa": "long-acting injectable antipsychotic", "experience": "Dossiers"}, {"person": "Ellie Manca", "diseaseState": "COVID-19", "drugName": "AT-527", "drugMoa": "antiviral, polymerase inhibitor", "experience": "Gap analysis"}, {"person": "Ellie Manca", "diseaseState": "Women's health, contraceptives", "drugName": "Copper 175 mm2 IUD", "drugMoa": "Copper-releasing IUD", "experience": "Abstracts, slide decks"}, {"person": "Ellie Manca", "diseaseState": "MDS and AML", "drugName": "magrolimab", "drugMoa": "CD-47 targeting drug", "experience": "Manuscripts, abstracts"}, {"person": "Ellie Manca", "diseaseState": "Hemophilia", "drugName": "valoctocogene roxaparvovec", "drugMoa": "gene therapy", "experience": "Manuscript, abstracts, oral presentation"}, {"person": "Ellie Manca", "diseaseState": "Atrial fibrillation", "drugName": "edoxaban", "drugMoa": "direct-acting oral anticoagulant", "experience": "Manuscript"}, {"person": "Hameda Capitani", "diseaseState": "Multiple Sclerosis", "drugName": "Ozanimod", "drugMoa": "S1P receptor modulator that binds to S1P receptors 1 & 5 on lymphocytes", "experience": "advisory boards, speaker training, objection handler, storyboard, MOA video, landscape analyses"}, {"person": "Hameda Capitani", "diseaseState": "Gastrointestinal disease (inflammatory bowel disease, ulcerative colitis)", "drugName": "Ozanimod", "drugMoa": "S1P receptor modulator that binds to S1P receptors 1 & 5 on lymphocytes", "experience": "advisory boards, abstracts, oral presentations, posters"}, {"person": "Hameda Capitani", "diseaseState": "Breast cancer", "drugName": "Sacituzumab govitecan", "drugMoa": "Trop-2-directed antibody and topoisomerase inhibitor drug conjugate", "experience": "Abstracts, posters, oral presentations, manuscripts, publication planning, advisory boards, congress coverage"}, {"person": "Hameda Capitani", "diseaseState": "Lung cancer (NSCLC)", "drugName": "Sacituzumab govitecan", "drugMoa": "Trop-2-directed antibody and topoisomerase inhibitor drug conjugate", "experience": "advisory boards"}, {"person": "Hameda Capitani", "diseaseState": "Lung cancer (NSCLC)", "drugName": "Dostarlimab", "drugMoa": "PARP inhibitor", "experience": "Patient journey, landscape analyses"}, {"person": "Hameda Capitani", "diseaseState": "Gynecologic cancers (eg, ovarian cancer, endometrial cancer)", "drugName": "Niraparib", "drugMoa": "PARP inhibitor", "experience": "advisory boards"}, {"person": "Hameda Capitani", "diseaseState": "Gynecologic cancers (eg, ovarian cancer, endometrial cancer)", "drugName": "Dostarlimab", "drugMoa": "PARP inhibitor", "experience": "advisory boards"}, {"person": "Hameda Capitani", "diseaseState": "Large B-cell lymphoma/non-Hodgkin's lymphoma", "drugName": "Axicabtagene ciloleucel (axi-cel)", "drugMoa": "CAR T-cell therapy", "experience": "Abstracts, posters, oral presentations, manuscripts, publication planning"}, {"person": "Chuck Blajszczak", "diseaseState": "Kidney and stem cell transplant", "drugName": "FCR001", "drugMoa": "allogeneic stem cell therapy and organ transplant or systemic sclerosis/scleroderma", "experience": "Manuscripts, abstracts, posters, oral presentations, SCP, lexicon, landscape analysis, gap/SWOT analaysis, publication plan, CME presentation, MSL slide decks, congress booth and handouts, patient facing education materials, ad board, monographs, 1 page summaries/infographics"}, {"person": "Chuck Blajszczak", "diseaseState": "IgA Nephropathy/focal segmental glomerulosclerosis", "drugName": "Sparsentan", "drugMoa": "dual endothelin angiotensin receptor antagonist (DEARA)", "experience": "ad boards"}, {"person": "Chuck Blajszczak", "diseaseState": "Rare pediatric neurodegenerative diseases", "drugName": "AAV9-based gene therapy", "drugMoa": "CNS targeted delivery of engineered AAV9 vectors for rare monogeneic neurodegenerative diseases", "experience": "dossiers, lexicons, manuscripts, systematic literature review, 1 page summaries"}, {"person": "Chuck Blajszczak", "diseaseState": "Phenylketouria", "drugName": "Kuvan / pegvaliase", "drugMoa": "BH4/ phenylalanine metabolizing enzyme", "experience": "SCP"}, {"person": "Chuck Blajszczak", "diseaseState": "Obesity", "drugName": "Contrave", "drugMoa": "fixed-dose extended-release combination of naltrexone and bupriorion synergistically targeting hunger cues via POMC neurons", "experience": "Manuscripts and letters to the editor, Systematic literature review, editorial board, publication plan"}, {"person": "Chuck Blajszczak", "diseaseState": "HIV/AIDs", "drugName": "EBT101", "drugMoa": "CRISPER-Cas9, gene therapy", "experience": "Oral presentations, manuscripts"}, {"person": "Chuck Blajszczak", "diseaseState": "HBV and HDV", "drugName": "Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide", "drugMoa": "antiviral", "experience": "Manuscripts, posters, abstracts"}, {"person": "Chuck Blajszczak", "diseaseState": "Cardioascular disease (atrial fibrillation)", "drugName": "Edoxaban", "drugMoa": "Factor Xa", "experience": "Abstracts (including encores), posters, oral presentations, manuscripts"}, {"person": "Ryan Coleman", "diseaseState": "Hereditary angioedema", "drugName": "Donidalorsen", "drugMoa": "GalNAc-conjugated antisense oligonucleotide targeting plasma prekallikrein mRNA", "experience": "Publication plan support and refresh workshop, SCP, abstracts, manuscripts, posters, slide decks, scripts, audiovisual poster presentations"}, {"person": "Ryan Coleman", "diseaseState": "Posttraumatic stress disorder", "drugName": "Midomafetamine-assisted therapy (no longer supporting)", "drugMoa": "Entactogen targeting 5-HT2 receptor", "experience": "Manuscript, publication errata, treatment manual"}, {"person": "Ryan Coleman", "diseaseState": "Major depressive disorder", "drugName": "Zuranolone", "drugMoa": "PAM of GABA A receptors and NAS", "experience": "Manuscripts, posters, abstracts, slide decks"}, {"person": "Ryan Coleman", "diseaseState": "Postpartum depressive disorder", "drugName": "Zuranolone; Brexanolone", "drugMoa": "PAM of GABA A receptors and NAS", "experience": "Manuscripts, posters, abstracts, slide decks"}, {"person": "Ryan Coleman", "diseaseState": "Cardioascular disease (atrial fibrillation)", "drugName": "Edoxaban", "drugMoa": "Factor Xa", "experience": "Abstracts (including encores), posters, oral presentations, manuscripts"}, {"person": "Ryan Coleman", "diseaseState": "Facial wrinkles and folds", "drugName": "Hyaluronic acid filler", "drugMoa": "N/A; injected filler gel", "experience": "Manuscript"}, {"person": "ASD", "diseaseState": "Advanced melanoma", "drugName": "RP1 (vusolimogene oderparepvec)", "drugMoa": "Oncolyticimmunotherapy (HSV-1-based)", "experience": "Abstracts"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis delta virus", "drugName": "Hepcludex (Bulevertide)", "drugMoa": "HDV viral entry inhibitor", "experience": "manuscripts, abstract, slide decks"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis delta virus", "drugName": "ABI-6250", "drugMoa": "HDV viral entry inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "Vemildy (tenofovir alafenamide)", "drugMoa": "Polymerase inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "Viread (tenofovir disoproxil fumarate)", "drugMoa": "Polymerase inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "Selgantolimod", "drugMoa": "TLR8-agonist", "experience": "Manuscript"}, {"person": "ASD", "diseaseState": "mNSCLC", "drugName": "Trodelvy (sacituzumab govitecan)", "drugMoa": "Trop-2-directed antibody conjugate", "experience": "Abstracts"}, {"person": "ASD", "diseaseState": "HIV infection", "drugName": "Sunlenca (lenacpavir)", "drugMoa": "Capsid inhibitor", "experience": "Manuscripts"}, {"person": "ASD", "diseaseState": "Rheumatoid arthritis", "drugName": "Jyseleca (filgotinib)", "drugMoa": "JAK-1 inhibtor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "Vebicorvir", "drugMoa": "core inhibitor/capsid assembly modulator", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "ABI-H2158", "drugMoa": "core inhibitor/capsid assembly modulator", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "ABI-H3733", "drugMoa": "core inhibitor/capsid assembly modulator", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "ABI-4334", "drugMoa": "core inhibitor/capsid assembly modulator", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Chronic infection with hepatitis B virus", "drugName": "AB-091", "drugMoa": "IFNAR agonist", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "HSV infection", "drugName": "ABI-5366", "drugMoa": "helicase primase inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "COPD", "drugName": "Yuperli (revefenacin)", "drugMoa": "Long-acting muscarinic receptor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Neurogenic orthostatic hypotension", "drugName": "Ampreloxetine", "drugMoa": "Norephinephrine reuptake inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations"}, {"person": "ASD", "diseaseState": "Lupus (SLE, LN, DLE)", "drugName": "Dadxilimab", "drugMoa": "IL-7 inhibitor", "experience": "Manuscripts, abstracts, posters, oral presentations, SCP"}, {"person": "ASD", "diseaseState": "Sjogren's", "drugName": "Dazodalibep", "drugMoa": "CD40 ligand antagonist", "experience": "Manuscripts, abstracts, posters, oral presentations, SCP"}, {"person": "ASD", "diseaseState": "Diffuce cutaneous systemic sclerosis, idopathic pulmonary fibrosis", "drugName": "Fipaxalparant", "drugMoa": "LPAR1 negative allosteric modulator", "experience": "Manuscripts, abstracts, posters, oral presentations, SCP,"}, {"person": "ASD", "diseaseState": "IgG4-RD,myasthenia gravis", "drugName": "UPLIZNA (ineblizumab)", "drugMoa": "CD19 depleter", "experience": "Manuscript, med info letter, poster, abstract"}, {"person": "ASD", "diseaseState": "Duchenne's muscular dystrophy", "drugName": "viltolarsen", "drugMoa": "Exon 53-skipping antisense oligonucleotide", "experience": "Manuscript, poster"}, {"person": "ASD", "diseaseState": "Postpartum depression", "drugName": "Zurzuvae (zuranalone)", "drugMoa": "GABA receptor positive allosteric modulator", "experience": "Manuscripts"}, {"person": "ASD", "diseaseState": "Gout", "drugName": "KRYSTEXXA (pegloticase)", "drugMoa": "peglyated uric acid specific enzyme", "experience": "Manuscripts"}, {"person": "ASD", "diseaseState": "Psoriatic artritis, plaque psorisis", "drugName": "OTEZLA (apremilast)", "drugMoa": "phsophodiaesterase 4", "experience": "Med info letter, posters, abstracts, slide decks, interactive PDFs"}, {"person": "ASD", "diseaseState": "antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides", "drugName": "TAVNEOS (avacopan)", "drugMoa": "complement 5a receptor antagonist", "experience": "Med info letter, posters, abstracts, slide decks, interactive PDFs"}, {"person": "ASD", "diseaseState": "SCLC", "drugName": "IMDELTRA (tarlatamab)", "drugMoa": "bispecific t-cell engager", "experience": "Poster, Manuscript"}, {"person": "ASD", "diseaseState": "Refractory B-cell precursor acute lymphoblastic lekemia", "drugName": "BLINCYTO (blinatumomab)", "drugMoa": "bispecific t-cell engager", "experience": "Slide deck"}, {"person": "ASD", "diseaseState": "Solid tumor cancers", "drugName": "bemarituzumab", "drugMoa": "fibroblast growth factor receptor type 2b binder", "experience": "Manuscript"}, {"person": "SD", "diseaseState": "Psoriatic Arthritis", "drugName": "Cimzia (certolizumab)", "drugMoa": "TNF inhibitor", "experience": "Competitive intelligence, unbranded disease decks"}, {"person": "SD", "diseaseState": "Plaque psoriasis", "drugName": "Cosentyx (secukinumab)", "drugMoa": "IL-17 inhibitor", "experience": "Unbranded symposia, interactive med affairs booth materials, patient journey videos, digital application"}, {"person": "SD", "diseaseState": "Inflammatory bowel disease", "drugName": "Rinvoq (upadacitinib)", "drugMoa": "JAK inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "Rheumatoid arthritis", "drugName": "Cimzia (certolizumab)", "drugMoa": "TNF inhibitor", "experience": "Competitive intelligence, unbranded disease decks"}, {"person": "SD", "diseaseState": "Axial spondyloarthritis", "drugName": "Cimzia (certolizumab)", "drugMoa": "TNF inhibitor", "experience": "Competitive intelligence, unbranded disease decks"}, {"person": "SD", "diseaseState": "Generalized pustular psoriasis", "drugName": "SPEVIGO (spesolimab-sbzo)", "drugMoa": "IL-36 inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "Hypertrophic cardiomyopathy", "drugName": "Camzyos (mavacamten)", "drugMoa": "cardiac myosin inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "Heart failure", "drugName": "Entresto (sacubitril and valsartan)", "drugMoa": "neprilysin inhibitor (sacubitril), angiotensin receptor blocker (valsartan)", "experience": "Symposia decks, booth materials, webcasts, enduring symposia videos"}, {"person": "SD", "diseaseState": "Triple negative breast cancer", "drugName": "Keytruda (pembrolizumab)", "drugMoa": "PD-1 inhibitor", "experience": "abstracts, posters, oral presentations, manuscripts"}, {"person": "SD", "diseaseState": "Gastric cancer", "drugName": "Keytruda (pembrolizumab)", "drugMoa": "PD-1 inhibitor", "experience": "abstracts, posters, oral presentations, manuscripts"}, {"person": "SD", "diseaseState": "Atherosclerosis", "drugName": "Ilaris (canakinumab)", "drugMoa": "IL-1\u03b2 blocker", "experience": "Symposia decks"}, {"person": "SD", "diseaseState": "Atopic dermatitis", "drugName": "Rinvoq (upadacitinib)", "drugMoa": "JAK inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "HIV PrEP", "drugName": "Apretude (cabotegravir)", "drugMoa": "HIV-1 integrase strand transfer inhibitor (INSTI) indicated for PrEP", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "HIV treatment", "drugName": "BIKTARVY\u00ae (bictegravir, emtricitabine, and tenofovir alafenamide)", "drugMoa": "bictegravir, a HIV-1 integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs)", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "HBV", "drugName": "tenofovir alafenamide", "drugMoa": "", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "CMV", "drugName": "mRNA-1647", "drugMoa": "CMV vaccine", "experience": "Abstracts, posters, oral presentations, manuscripts, reviews"}, {"person": "SD", "diseaseState": "COVID-19", "drugName": "Spikevax (mRNA vaccine)", "drugMoa": "mRNA vaccine", "experience": "Advisory board meeting materials,commercial narratives, workshops"}, {"person": "SD", "diseaseState": "Kidney transplantation", "drugName": "Thymoglobulin (anti-thymocyte globulin)", "drugMoa": "anti-thymocyte polyclonal antibody", "experience": "MSL training modules, scientific communication platform, speaker's bureau materials, advidosry board materials"}, {"person": "SD", "diseaseState": "Deep partial-thickness burns", "drugName": "Stratagraft ((allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat)", "drugMoa": "allogeneic cellularized scaffold product", "experience": "Narrative reviews, posters, oral presentations"}, {"person": "SD", "diseaseState": "Chronic spontaneous urticaria", "drugName": "Remibrutinib", "drugMoa": "BTK inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "Chronic Active Antibody-Mediated Rejection", "drugName": "Cazaklizumab", "drugMoa": "IL-6 inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "Irritable bowel syndrome", "drugName": "Ibsrela (tenapanor)", "drugMoa": "sodium/hydrogen exchanger 3 (NHE3) inhibitor", "experience": "Gap analyses, CME presentations, practice aids"}, {"person": "SD", "diseaseState": "Graves' disease", "drugName": "Batoclimab\nIMVT-1402", "drugMoa": "FcRn inhibitors", "experience": "Pub planning, SCP, manuscripts, booth trial handout, interactive tool, MSL deck, symposia"}, {"person": "SD", "diseaseState": "Thyroid eye disease", "drugName": "", "drugMoa": "", "experience": "Pub planning, manuscript"}, {"person": "SD", "diseaseState": "Myasthenia gravis", "drugName": "", "drugMoa": "", "experience": "Pub planning, Literature analysis"}, {"person": "SD", "diseaseState": "Chronic inflammatory demyelinating polyradiculoneuropathy", "drugName": "", "drugMoa": "", "experience": "Pub planning, SCP, manuscripts"}, {"person": "SD", "diseaseState": "Rheumatoid arthritis", "drugName": "", "drugMoa": "", "experience": "Pub planning, SCP, booth trial handout"}, {"person": "SD", "diseaseState": "Sjogren's disease", "drugName": "", "drugMoa": "", "experience": "Disease deck"}], "writerExperience": [{"name": "Stephanie Justice-Bitner", "startDate": "2023-11-27", "therapeuticArea": "Atrial fribilation (RN)", "drugNameMoa": "Edoxaban (inhibits FXa)", "academicBackground": "opioid dependence"}, {"name": "Stephanie Justice-Bitner", "startDate": "2023-11-27", "therapeuticArea": "Systemic mastocytosis (RN)", "drugNameMoa": "Avapritinib (tyrosine kinase inhibitor)", "academicBackground": "infectious diseases"}, {"name": "Stephanie Justice-Bitner", "startDate": "2023-11-27", "therapeuticArea": "HRS-AKI (RN)", "drugNameMoa": "terlipressin (vasopressin receptor agonist)", "academicBackground": "Allergy"}, {"name": "Stephanie Justice-Bitner", "startDate": "2023-11-27", "therapeuticArea": "Spinal muscular atrophy (RN)", "drugNameMoa": "apitemogromab (myostatin inhibitor)", "academicBackground": "inflammatory diseases"}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Basal cell carcinoma (RN)", "drugNameMoa": "Sonidegib (Odomzo; Hedgehog pathway inhibitor)", "academicBackground": "Cardiovascular physiology"}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Metastatic castration-resistant prostate cancer (RN)", "drugNameMoa": "Abiraterone acetate (Yonsa; CYP17 inhibitor)", "academicBackground": "Ischemia-reperfusion injury"}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Major depressive disorder/postpartum depressive disorder (RN)", "drugNameMoa": "Zuranolone (Zurzuvae; GABA receptor positive allosteric modulator) & brexanolone (Zulresso; GABA receptor positive allosteric modulator)", "academicBackground": "Metabolism/bioenergetics"}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Attention deficit hyperactivity disorder (RN)", "drugNameMoa": "Viloxazine extended-release (Qelbree; norepinephrine reuptake inhibitor)", "academicBackground": ""}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Multiple sclerosis (RN)", "drugNameMoa": "Amantadine extended-release (Gocovri; NMDA receptor antagonist)", "academicBackground": ""}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Myelodysplastic syndromes (RN)", "drugNameMoa": "Imetelstat (telomerase inhibitor)", "academicBackground": ""}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Chronic inflammatory demyelinating polyneuropathy (RN)", "drugNameMoa": "Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)", "academicBackground": ""}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Chronic myeloid leukemia (RN)", "drugNameMoa": "Vodobatinib (BCR::ABL1 inhibitor)", "academicBackground": ""}, {"name": "Alexander Milliken", "startDate": "2022-10-17", "therapeuticArea": "Dry eye disease (RN)", "drugNameMoa": "Cyclosporine ophthalmic solution 0.09% (Cequa)", "academicBackground": ""}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya, anti-IL-23 antibody)", "academicBackground": "Synaptic plasticity"}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "Alopecia areata", "drugNameMoa": "Deuruxolitinib (JAK1 & 2 inhibitor)", "academicBackground": "Substance use disorder"}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "Actinic keratoses", "drugNameMoa": "Aminolevulinic acid (Levulan, porphyrin precursor)", "academicBackground": "Neuroscience"}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Clascoterone cream (Winlevi, topical androgen inhibitor)", "academicBackground": ""}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Isotretinoin (Absorica and Absorica LD, retinoic acid receptor agonist)", "academicBackground": ""}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "COPD", "drugNameMoa": "Revefenacin (long-acting muscarinic antagonist)", "academicBackground": ""}, {"name": "Melissa Knouse", "startDate": "2023-06-05", "therapeuticArea": "MSA", "drugNameMoa": "Ampreloxetine (norephinephrine reuptake inhibitor)", "academicBackground": ""}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Chronic infection with HDV; HEOR and Tx", "drugNameMoa": "Hepcludex (bulevirtide)", "academicBackground": "Diabetes"}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Vemlidy (tenofovir alafenamide), Viread (tenofovir disoproxil fumarate); polymerase inhibitors", "academicBackground": "Cardiac function"}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "selgantolimod; TLR8-agonist", "academicBackground": "Mitochondrial function"}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Chronic infection with HCV", "drugNameMoa": "", "academicBackground": "Pulmonary"}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "HIV infection", "drugNameMoa": "Sunlenca (lenacapavir); capsid inhibitor", "academicBackground": "Skeletal muscle"}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Rheumatoid arthritis", "drugNameMoa": "Jyseleca (filgotinib); JAK-1 inhibitor", "academicBackground": "Exercise physiology"}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Neuromyelistis optica spectrum disorder (NMOSD)", "drugNameMoa": "Rituximab (RTX), Eculizumab (ECU), C5 complement inhibitors (C5IT)", "academicBackground": ""}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Acute Myeloid Leukemia (AML)", "drugNameMoa": "TP53 mutation", "academicBackground": ""}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "Prostate Cancer", "drugNameMoa": "ARV-766, ARV-393, Bavdegalutamide", "academicBackground": ""}, {"name": "Danielle Rubin-Shepherd", "startDate": "2022-07-11", "therapeuticArea": "ER+/HER2- breast cancer", "drugNameMoa": "Vepdegestrant; PROTAC ER degrader", "academicBackground": ""}, {"name": "Samantha Tener", "startDate": "2024-02-05", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Vemlidy (tenofovir alafenamide); polymerase inhibitor", "academicBackground": "circadian rhythms"}, {"name": "Samantha Tener", "startDate": "2024-02-05", "therapeuticArea": "Chronic infection with HCV; HEOR", "drugNameMoa": "", "academicBackground": "sleep"}, {"name": "Samantha Tener", "startDate": "2024-02-05", "therapeuticArea": "Chronic infection with HDV; HEOR", "drugNameMoa": "Hepcludex (bulevirtide); NTCP inhibitor", "academicBackground": "metabolism (particularly lipid metabolism, metabolism related to intermittant fasting)"}, {"name": "Samantha Tener", "startDate": "2024-02-05", "therapeuticArea": "mTNBC", "drugNameMoa": "sacituzumab govitecan (Trodelvy); Trop-2-directed antibody drug conjugate", "academicBackground": "pathophysiology"}, {"name": "Samantha Tener", "startDate": "2024-02-05", "therapeuticArea": "Autoimmune diseases (Graves' disease, TED, CIDP, Sjogren's); related HEOR claims data", "drugNameMoa": "Batoclimab and IMVT-1402; anti-FcRn monoclonal antibodies", "academicBackground": "genetics"}, {"name": "Samantha Tener", "startDate": "2024-02-05", "therapeuticArea": "Ulcerative colitis", "drugNameMoa": "MORF-057; small-molecule a4b7 integrin inhibitor", "academicBackground": ""}, {"name": "Megan Rudolph", "startDate": "2024-02-05", "therapeuticArea": "Chronic infection with HDV; HEOR and Tx", "drugNameMoa": "Hepcludex (bulevirtide); NTCP-inhibitor", "academicBackground": "Neuroscience"}, {"name": "Megan Rudolph", "startDate": "2024-02-05", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Vemlidy (tenofovir alafenamide), Viread (tenofovir disoproxil fumarate); polymerase inhibitors", "academicBackground": "Traumatic brain injuries and post-traumatic headache"}, {"name": "Megan Rudolph", "startDate": "2024-02-05", "therapeuticArea": "Chronic infection with HCV", "drugNameMoa": "", "academicBackground": "Migraine/headache disorders"}, {"name": "Megan Rudolph", "startDate": "2024-02-05", "therapeuticArea": "Complement-mediated conditions (NMOSD, gMH, PNH, aHUS)", "drugNameMoa": "Soliris (eculizumab); C5 inhibitor", "academicBackground": "Neuropsychiatric disorders (anxiety, depression)"}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "IgG4-RD", "drugNameMoa": "UPLIZNA (inebilizumab); CD19+ cell depleter", "academicBackground": "Neuroscience"}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "Lupus (SLE, LN, DLE)", "drugNameMoa": "Daxdilimab; IL7 inhibitor", "academicBackground": "Neurodegenerative disease"}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "Sjogren's", "drugNameMoa": "Dazodalibep; CD40L antagonist", "academicBackground": "Cell Biology (primarily cytoskeleton function)"}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "Gout", "drugNameMoa": "Pegloticase (KRYSTEXXA); PEGylated uric acid specific enzyme", "academicBackground": "Cell division abnormalities (cancer, reproductive health)"}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "Uveal melanoma", "drugNameMoa": "RP2 (oncolytic virus; modified HSV-1)", "academicBackground": ""}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "Cancer (solid tumors, including anti-PD-1-failed melanoma)", "drugNameMoa": "RP1 (oncolytic virus; modified HSV-1)", "academicBackground": ""}, {"name": "Claire Strothman", "startDate": "2023-04-20", "therapeuticArea": "Thyroid eye disease", "drugNameMoa": "Lonigutamab; anti-IGF-1R mAb", "academicBackground": ""}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Clascoterone (topical androgen receptor inhibitor); Absorica (lidose isotretinoin) and Absorica LD (micronized isotretinoin)", "academicBackground": "Neuroscience"}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tilrakizumab (Inhibits IL-23 p19 subunit)", "academicBackground": "Brain injury and stroke"}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Actinic keratosis", "drugNameMoa": "Aminolevulinic acid/photodynamic therapy (ALA is metabolized to protoporphyrin IX; when activated by light, it forms ROS that cause cell death)", "academicBackground": "Neuropsychiatric and substance use disorders"}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Alexander disease", "drugNameMoa": "Zilganersen (antisense oligonucleotide designed to reduce levels of GFAP protein)", "academicBackground": "Neurodegenerative disease"}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Prion disease", "drugNameMoa": "ION717 (antisense oligonucleotide designed to reduce levels of prion protein)", "academicBackground": "Stem cell therapies"}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Angelman syndrome", "drugNameMoa": "ION582 (antisense oligonucleutode designd to unsilence the paternal UBE3A allelle)", "academicBackground": ""}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Diabetes/obesity", "drugNameMoa": "GL0034 (GLP-1 receptor agonist)", "academicBackground": ""}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Congenital ichthyosis", "drugNameMoa": "TMB-001 (topical isotretinoin)", "academicBackground": ""}, {"name": "Dana Lengel", "startDate": "2022-06-08", "therapeuticArea": "Infectious disease/fungal infections", "drugNameMoa": "Fosmanogepix (prodrug of manogepix with broad-spectrum activity against yeasts and molds)", "academicBackground": ""}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Chronic infection with HDV; HEOR and Tx", "drugNameMoa": "Hepcludex (bulevirtide)", "academicBackground": "HIV"}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Vemlidy (tenofovir alafenamide), Viread (tenofovir disoproxil fumarate); polymerase inhibitors", "academicBackground": "SARS-CoV-2"}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "selgantolimod; TLR8-agonist", "academicBackground": "Immunology"}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Chronic infection with HCV", "drugNameMoa": "Epclusa (sofosbuvir/velpatasvir)", "academicBackground": "Infectious diseases"}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Rheumatoid arthritis", "drugNameMoa": "Jyseleca (filgotinib); JAK-1 inhibitor", "academicBackground": "Virology"}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Oncology: mTNBC", "drugNameMoa": "sacituzumab govitecan (Trodelvy); Trop-2-directed antibody drug conjugate", "academicBackground": "Public health"}, {"name": "Olivia Harwood", "startDate": "2023-11-06", "therapeuticArea": "Oncology: mNSCLC", "drugNameMoa": "sacituzumab govitecan (Trodelvy); Trop-2-directed antibody drug conjugate", "academicBackground": ""}, {"name": "Johnson Ying", "startDate": "2023-04-17", "therapeuticArea": "Major depressive disorder/postpartum depressive disorder", "drugNameMoa": "Zuranolone (Zurzuvae; GABA receptor positive allosteric modulator)", "academicBackground": "Neuroscience, neurocircuitry, rodent models, in-vivo recordings during behavior"}, {"name": "Johnson Ying", "startDate": "2023-04-17", "therapeuticArea": "Congenital ichthyosis", "drugNameMoa": "TMB-001 (topical isotretinoin)", "academicBackground": "Alzheimer's disease"}, {"name": "Johnson Ying", "startDate": "2023-04-17", "therapeuticArea": "Familial chylomicronemia syndrome; hypertriglyceridemia", "drugNameMoa": "Olezarsen (APOC3 ASO)", "academicBackground": ""}, {"name": "Johnson Ying", "startDate": "2023-04-17", "therapeuticArea": "Chronic inflammatory demyelinating polyneuropathy", "drugNameMoa": "Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)", "academicBackground": ""}, {"name": "Johnson Ying", "startDate": "2023-04-17", "therapeuticArea": "Huntington's disease", "drugNameMoa": "SAGE-718 (Dalzanemdor; NMDAR allosteric modulator)", "academicBackground": ""}, {"name": "Johnson Ying", "startDate": "2023-04-17", "therapeuticArea": "Seizures and epilepsy", "drugNameMoa": "Med affairs content with Neurelis", "academicBackground": ""}, {"name": "Ryan Reynolds", "startDate": "2023-07-10", "therapeuticArea": "Dry eye disease", "drugNameMoa": "Cequa, cyclosporine (calcineurin inhibitor)", "academicBackground": "Neuroscience (preclinical): depression, radiation"}, {"name": "Ryan Reynolds", "startDate": "2023-07-10", "therapeuticArea": "Basal cell carcinoma", "drugNameMoa": "Odomzo, sonidegib (sonic hedgehog inhibitor)", "academicBackground": "Neuroscience (preclinical): learning and memory"}, {"name": "Ryan Reynolds", "startDate": "2023-07-10", "therapeuticArea": "Metastatic castration-resistant prostate cancer", "drugNameMoa": "Yonsa, abiraterone acetate (CYP17 inhibitor)", "academicBackground": "Metabolism (preclinical): diabetes and obesity"}, {"name": "Ryan Reynolds", "startDate": "2023-07-10", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Winlevi, clascoterone cream (adrogen receptor inhibitor)", "academicBackground": "Hypothalamic regulation of whole-body metabolism"}, {"name": "Ryan Reynolds", "startDate": "2023-07-10", "therapeuticArea": "Hereditary angioedema", "drugNameMoa": "Donidalorsen, antisense oligonucleotide (prekallikrein mRNA inhibitor)", "academicBackground": "Inflammatory responses (preclinical): sepsis"}, {"name": "Ryan Reynolds", "startDate": "2023-07-10", "therapeuticArea": "Neonatal seizures", "drugNameMoa": "Sezaby, phenobarbital (GABAaR agonist)", "academicBackground": ""}, {"name": "Sylvia Stankov", "startDate": "2023-07-25", "therapeuticArea": "Chronic hepatitis B virus infection; chronic herpes virus infection", "drugNameMoa": "Vebicorvir,  ABI-4334 (core inhibitor/capsid assembly modulator); ABI-1179 and ABI-5366 (helicase-primase inhibitors)", "academicBackground": "Lipid and lipoprotein metabolism; cardiovascular disease"}, {"name": "Sylvia Stankov", "startDate": "2023-07-25", "therapeuticArea": "Psoriatic arthritis", "drugNameMoa": "Izokibep (IL-17A inhibitor)", "academicBackground": "Gene editing, gene therapy (CRISPR, AAV, lentivirus)"}, {"name": "Sylvia Stankov", "startDate": "2023-07-25", "therapeuticArea": "Hidradenitis suppurativa", "drugNameMoa": "Izokibep (IL-17A inhibitor)", "academicBackground": "Naturally-occuring genetic variation (loss- and gain-of-function mutations); EHR-linked biobanks"}, {"name": "Sylvia Stankov", "startDate": "2023-07-25", "therapeuticArea": "Thyroid eye disease", "drugNameMoa": "Lonigutamab (anti-IGF-1R mAb)", "academicBackground": "Protein structure-function"}, {"name": "Sylvia Stankov", "startDate": "2023-07-25", "therapeuticArea": "Familial chylomicronemia syndrome; hypertriglyceridemia", "drugNameMoa": "Olezarsen (APOC3 ASO)", "academicBackground": "Pompe disease"}, {"name": "Tony Sallese", "startDate": "2022-06-08", "therapeuticArea": "Gene therapy (AAV vector) and Hemophilia", "drugNameMoa": "valoctocogene roxaparvovec (AAV vector)", "academicBackground": "graduate degree in rare lung disease caused by defective immune response and pulmonary surfactant accumulation. Postdoctoral work in immunology and injury response/tissue repair. Also some expereince with mass spectrometry and lipid metabolism"}, {"name": "Tony Sallese", "startDate": "2022-06-08", "therapeuticArea": "Antisense oligonucleotide therapy and Duchenne muscular dystrophy", "drugNameMoa": "BMN 351 (antisense oligonucleotide)", "academicBackground": ""}, {"name": "Tony Sallese", "startDate": "2022-06-08", "therapeuticArea": "Cancer (solid tumors) and immune checkpoint resistance", "drugNameMoa": "Linavonkibart (anti-Latent TGF beta 1)", "academicBackground": ""}, {"name": "Tony Sallese", "startDate": "2022-06-08", "therapeuticArea": "Cancer and oncolytic immunotherapy", "drugNameMoa": "RP1 (oncolytic virus)", "academicBackground": ""}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Selgantolimod, TLR8-agonist; GS-4224, PD-1 inhibitor", "academicBackground": "Herpes simplex virus"}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Chronic infection with HDV", "drugNameMoa": "Hepcludex (bulevirtide), NTCP-inhibitor", "academicBackground": "Virology"}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Chronic infection with HCV", "drugNameMoa": "", "academicBackground": ""}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Diffuse cutaneous systemic sclerosis, idiopathic pulmonary fibrosis", "drugNameMoa": "HZN-825/fipaxalparant, LPAR1 antagonist", "academicBackground": "Bioinformatics"}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Stroke prevention in AF, secondary prevention in VTE", "drugNameMoa": "Edoxaban, factor Xa inhibitor", "academicBackground": ""}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Actinic keratosis", "drugNameMoa": "Aminolevulinic acid (Levulan), photosensitizer/photodynamic therapy", "academicBackground": ""}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Contraceptives", "drugNameMoa": "VeraCept (Miudella), copper IUD", "academicBackground": ""}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Scleroderma, kidney transplant", "drugNameMoa": "FCR001, allogenic stem cell therapy", "academicBackground": ""}, {"name": "Molly Yeager", "startDate": "2022-10-17", "therapeuticArea": "Pseudoxanthoma elasticum", "drugNameMoa": "DS-1211", "academicBackground": ""}, {"name": "Nitish Chaudhari", "startDate": "2022-08-08", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya, anti-IL-23 antibody)", "academicBackground": "Drugs of abuse/addiction"}, {"name": "Nitish Chaudhari", "startDate": "2022-08-08", "therapeuticArea": "Alopecia areata", "drugNameMoa": "Deuruxolitinib (JAK1 & 2 inhibitor)", "academicBackground": "Neuroscience/neurobiology"}, {"name": "Nitish Chaudhari", "startDate": "2022-08-08", "therapeuticArea": "Actinic keratoses", "drugNameMoa": "5-aminolevulinic acid (Levulan, porphyrin precursor)", "academicBackground": "Infectious diseases (HIV-1, RSV, Influenza)"}, {"name": "Nitish Chaudhari", "startDate": "2022-08-08", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Clascoterone cream (Winlevi, androgen receptor inhibitor)", "academicBackground": "Allergic diseases"}, {"name": "Nitish Chaudhari", "startDate": "2022-08-08", "therapeuticArea": "End-stage kidney disease", "drugNameMoa": "MK-2060 (Factor XI inhibitor)", "academicBackground": "Immunology"}, {"name": "Nitish Chaudhari", "startDate": "2022-08-08", "therapeuticArea": "Breast cancer", "drugNameMoa": "Capivasertib (Pan-AKT inhibitor)", "academicBackground": "Intergrin biology"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Rare sarcoma - Gastrointestinal Stromal Tumor", "drugNameMoa": "Ripretinib; KIT/PDGFRA tyrosine kinase inhibitor", "academicBackground": "Autoimmunity (primarily systemis lupus erythemathosus)"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Rare sarcoma - Tenosynovial Giant Cell Tumor", "drugNameMoa": "Vimseltinib; CSF1R inhibitor", "academicBackground": "Cell death (necrosis, apoptosis, necroptosis)/Danger signals"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "RAS/RAF-mutant cancers", "drugNameMoa": "DCC-3116; ULK1/2 kinase-mediated autophagy inhibitor", "academicBackground": "Role of estrogen in autoimmunity"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Rare sarcoma - Gastrointestinal Stromal Tumor", "drugNameMoa": "DCC-3009; KIT/PDGFRA tyrosine kinase inhibitor", "academicBackground": "Solid organ transplantation"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Advanced Breast Cancer", "drugNameMoa": "Vepdegestrant; PROTAC estrogen receptor degrader", "academicBackground": "Innate immune responses/cells"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Neuroautoimmune disorders - Neuromyelitis optica spectrum disorder", "drugNameMoa": "Rituximab (anti-CD20 antibody), eculizumab (anti-C5 antibody)", "academicBackground": "Dendritic cell biology"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Hematologic oncology - Non-Hodgkin lymphoma", "drugNameMoa": "CB-010; next-generation allogeneic CAR-T cell therapy with PD-1 knockout", "academicBackground": "HIV/mechanisms of immune cell response impairment in HIV"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Hematologic oncology - Multiple myeloma", "drugNameMoa": "CB-011; BCMA-specific allogeneic CAR-T cell therapy with HLA-E fusion transgene", "academicBackground": "T follicular helper cells"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Hematologic oncology - Acute myeloid leukemia", "drugNameMoa": "CB-012; allogeneic anti-CLL CAR-T cell therapy with PD-1 knockout and immune cloaking", "academicBackground": "Role of adenosine deaminase-1 in T follicular helper cell biology"}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Solid tumors (colorectal cancer, head and neck cancer, hepatocellular carcinoma, melanoma)", "drugNameMoa": "RP1, RP2, RP3; oncolytic virus therapy (modified HSV-1)", "academicBackground": ""}, {"name": "Marita Chakhtoura", "startDate": "2022-10-17", "therapeuticArea": "Osteoarthritis of the knee", "drugNameMoa": "MM-II; intra-articular injection of multilamellar liposomes", "academicBackground": ""}, {"name": "Allison Yankey", "startDate": "2023-07-10", "therapeuticArea": "Rare sarcoma - Gastrointestinal stromal tumor", "drugNameMoa": "ripretinib (tyrosine-kinase inhibitor)", "academicBackground": "non-coding RNA structure-function"}, {"name": "Allison Yankey", "startDate": "2023-07-10", "therapeuticArea": "Rare sarcoma - tenosynovial giant cell tumor", "drugNameMoa": "vimseltinib (colony stimulating factor 1 receptor inhibitor)", "academicBackground": "biofilm formation"}, {"name": "Allison Yankey", "startDate": "2023-07-10", "therapeuticArea": "Chronic infection with HCV", "drugNameMoa": "sofosbuvir (direct acting antiviral; NSFB inhibitor)", "academicBackground": "Protein structure-function"}, {"name": "Allison Yankey", "startDate": "2023-07-10", "therapeuticArea": "Non-small cell lung cancer", "drugNameMoa": "Trodelvy (sacituzumab govitecan; Trop-2 antibody)", "academicBackground": ""}, {"name": "Allison Yankey", "startDate": "2023-07-10", "therapeuticArea": "Duchenne muscular dystrophy (DMD)", "drugNameMoa": "NS-050 NS-089 (exon-skipping antisense oligonucleotide)", "academicBackground": ""}, {"name": "Allison Yankey", "startDate": "2023-07-10", "therapeuticArea": "Primary biliary cholangitis (PBC; liver; autoimmune)", "drugNameMoa": "Livdelzi (seladelpar; PPAR-delta agonist)", "academicBackground": ""}, {"name": "Steven Walker", "startDate": "2023-03-27", "therapeuticArea": "Rare sarcoma - gastrointestinal stromal tumor", "drugNameMoa": "ripretinib (tyrosine kinase inhibitor), DCC-3009", "academicBackground": "Optical Trapping"}, {"name": "Steven Walker", "startDate": "2023-03-27", "therapeuticArea": "Rare sarcoma - tenosynovial giant cell tumor", "drugNameMoa": "vimseltinib (tyrosine kinase inhibitor)", "academicBackground": "Single molecule biophysics"}, {"name": "Steven Walker", "startDate": "2023-03-27", "therapeuticArea": "Duchenne musculary dystrophy (DMD)", "drugNameMoa": "viltolarsen, NS-050, NS-089 (exon-skipping antisense oligonucleotides)", "academicBackground": "Biochemistry"}, {"name": "Steven Walker", "startDate": "2023-03-27", "therapeuticArea": "Multiple myeloma", "drugNameMoa": "CB-011 (anti-BCMA CAR-T cell)", "academicBackground": "AAA+ ATPases"}, {"name": "Elisabetta Lauretti", "startDate": "2021-01-05", "therapeuticArea": "Psoriatic Arthritis", "drugNameMoa": "Izokibep (IL-17Ainhibitor)", "academicBackground": "Alzheimer's Disease"}, {"name": "Elisabetta Lauretti", "startDate": "2021-01-05", "therapeuticArea": "Plaque Psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya; IL-23 inhibitor", "academicBackground": "Parkinson's Disease"}, {"name": "Elisabetta Lauretti", "startDate": "2021-01-05", "therapeuticArea": "Alopecia Areata", "drugNameMoa": "Deuroxolitinib (JAK1/2 inhibitor)", "academicBackground": "Dementia"}, {"name": "Elisabetta Lauretti", "startDate": "2021-01-05", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Clascoterone (Winlevi; androgen receptor inhibitor)", "academicBackground": "microRNA"}, {"name": "Elisabetta Lauretti", "startDate": "2021-01-05", "therapeuticArea": "Rare sarcomea, tenosynovial giant cell tumor", "drugNameMoa": "Vimseltinib (tyrosine kinase inhibitor)", "academicBackground": "Neuroscience/Neurobiology"}, {"name": "Elisabetta Lauretti", "startDate": "2021-01-05", "therapeuticArea": "Familial chylomicronemia syndrome", "drugNameMoa": "Olezarsen (APOC3 siRNA)", "academicBackground": "Autophagy"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Basal cell carcinoma", "drugNameMoa": "Sonidegib (Hedhehog inhibitor)", "academicBackground": "microRNAs"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Prostate cancer", "drugNameMoa": "Abiraterone acetate (Androgen biosynthesis inhibitor/CYP17 inhibitor)", "academicBackground": "Exosomes"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Knee osteoarthritis", "drugNameMoa": "MM-II (empty multilamellar liposomes reducing joint friction and wear)", "academicBackground": "Multiple myeloma"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Alopecia areata", "drugNameMoa": "Deuruxolitinib (JAK1/JAK2 inhibitor)", "academicBackground": "Acute Myeloid Leukemia"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Dry eye disease", "drugNameMoa": "Cyclosporine ophthalmic solution 0.09%", "academicBackground": "Blastic Plasmacytoid Dendritic cell neoplasm"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Open-angle glaucoma and ocular hypertension", "drugNameMoa": "Latanoprost ophthalmic emulsion 0.005%", "academicBackground": "Hematological cancers"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Congenital ichtyosis", "drugNameMoa": "Isotretinoin", "academicBackground": "Sex differences in cancer"}, {"name": "Juliette Bouyssou", "startDate": "2023-10-16", "therapeuticArea": "Neuromyelitis optica (NMOSD)", "drugNameMoa": "Eculizumab and ravulizumab", "academicBackground": ""}, {"name": "Somdutta Mukherjee", "startDate": "2023-09-25", "therapeuticArea": "Alopecia Areata", "drugNameMoa": "Deuruxolitinib (JAK1/JAK2 inhibitor)", "academicBackground": "human induced plurioptent and embryonic stem cells"}, {"name": "Somdutta Mukherjee", "startDate": "2023-09-25", "therapeuticArea": "Actinic keratosis", "drugNameMoa": "Aminolevulinic acid (Levulan; photosensitizer/photodynamic therapy", "academicBackground": "liver and pancreatic development"}, {"name": "Somdutta Mukherjee", "startDate": "2023-09-25", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya; IL-23 inhibitor)", "academicBackground": "Diabetes"}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya; IL-23 inhibitor)", "academicBackground": "Osteoporosis"}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Clascoterone (Winlevi; androgen receptor inhibitor)", "academicBackground": "Osteoarthristis"}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "COPD", "drugNameMoa": "Revefenacin; LAMA", "academicBackground": "BMP pathway"}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Neurogenic orthostatic hypotenesion", "drugNameMoa": "Ampreloxetine; norephinephrine reuptake inhibitor", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Lupus (SLE, LN, DLE)", "drugNameMoa": "Daxdilimab; IL7 inhibitor", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Kidney transplant", "drugNameMoa": "Dazodalibep; CD40L antagonist", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Sjogren's", "drugNameMoa": "Dazodalibep; CD40L antagonist", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Sjogren's", "drugNameMoa": "AMG329", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Diffuce cutaneous systemic sclerosis, idopathic pulmonary fibrosis", "drugNameMoa": "Fipaxalprant", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Gout", "drugNameMoa": "KRYSTEXXA (pegloticase)", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Thyroid eye disease", "drugNameMoa": "Tepezza (teprotumumab)", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "IgG4-RD", "drugNameMoa": "UPLIZNA (inebilizumab); CD19 cell depletor", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Myasthenia gravis", "drugNameMoa": "UPLIZNA (inebilizumab); CD19 depletor", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "COVID-19/lung transplant", "drugNameMoa": "Nezulcitinib", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "IBS/ Crohns/ Ulcerative colitis", "drugNameMoa": "Izencitinib", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Uveal melanoma", "drugNameMoa": "RP2 (oncolytic virus)", "academicBackground": ""}, {"name": "Hilary Durbano", "startDate": "2020-10-12", "therapeuticArea": "Cancer (solid tumors, including anti-PD-1-failed melanoma)", "drugNameMoa": "RP1 (oncolytic virus)", "academicBackground": ""}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Hemophilia", "drugNameMoa": "Valoctocogene roxaparvovec (Roctavian; AAV gene therapy)", "academicBackground": "Behavioral neuroscience (Cognition/aging)"}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Duchenne muscular dystrophy", "drugNameMoa": "BMN 351 (antisense oligonucleotide-based exon skipping)", "academicBackground": "Behavioral neuroscience (Cognition/addiction)"}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Hereditary angioedema types I and II", "drugNameMoa": "BMN 331 (AAV gene therapy)", "academicBackground": "Plant physiology (genotypic resilience to elevated ozone/heat)"}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Osteoarthritis", "drugNameMoa": "MM-II (lubrication using large, empty, multilamellar liposomes)", "academicBackground": "Food science (novel food processing techniques)"}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya; Anti-IL-23 monoclonal antibody)", "academicBackground": "Molecular neuroscience (temporal lobe epilepsy; mechanisms of sex differences in severity/astrocytic involvement)"}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Achondroplasia, hypochondroplasia, idiopathic short stature/growth-related conditions", "drugNameMoa": "Vosoritide (Voxzogo; C-type natriuretic peptide (CNP) analogue)", "academicBackground": "Molecular neuroscience (neural ensemble/molecular mechanisms/intracellular signaling underlying behavioral flexibility)"}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Alopecia areata", "drugNameMoa": "Deuruxolitinib (Leqselvi; JAK1/2 inhibitor)", "academicBackground": ""}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Obesity", "drugNameMoa": "Naltrexone and bupropion (Contrave; reward/satiety modulation)", "academicBackground": ""}, {"name": "Amin Ghane", "startDate": "2023-02-06", "therapeuticArea": "Oncology (solid tumors)", "drugNameMoa": "RP1 and RP2 (oncolytic virus)", "academicBackground": "Genetically encodable tools for tracking intracellular calcium signaling"}, {"name": "Breanne Pirino", "startDate": "2024-03-25", "therapeuticArea": "Obesity", "drugNameMoa": "Contrave (norepinepherine/dopamine reuptake inhibitor + mu opioid receptor antagonist)", "academicBackground": "Neuroscience (preclinical)"}, {"name": "Breanne Pirino", "startDate": "2024-03-25", "therapeuticArea": "HDV", "drugNameMoa": "Bulevirtide (HDV etry inhibitor)", "academicBackground": "Substance use disorders (alcohol)"}, {"name": "Breanne Pirino", "startDate": "2024-03-25", "therapeuticArea": "Rare disease (NMOSD, MG)", "drugNameMoa": "eculizumab, ravulizumab (C5IT inhibitors)", "academicBackground": "Endogenous opioids, neuropeptides"}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Multiple sclerosis", "drugNameMoa": "IFN (MOA unclear)", "academicBackground": "Public health"}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Respiratory allergy", "drugNameMoa": "Sublingual immunotherapy", "academicBackground": "Toxicology"}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Upper respiratory", "drugNameMoa": "Mometasone (steroid)", "academicBackground": "statistics"}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Cardiovascular", "drugNameMoa": "Apixaban (anticoagulant)", "academicBackground": ""}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Infectious disease (RSV, HIV, hepatitis)", "drugNameMoa": "ziresovir (fusion inhibitor), combivir (NRTI), Tenofovir alafenamide (NRTI)", "academicBackground": ""}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Paroxysmal nocturnal hemoglobinuria", "drugNameMoa": "MY008211A (complement factor B inhibitor)", "academicBackground": ""}, {"name": "Rob Coover", "startDate": "2021-04-26", "therapeuticArea": "Rheumatoid arthritis", "drugNameMoa": "filgotinib (JAKi)", "academicBackground": ""}, {"name": "Jake Wilmot", "startDate": "2024-05-06", "therapeuticArea": "Hereditary angioedema (allergy, hematology, rare disease)", "drugNameMoa": "donidalorsen, antisense oligonucleotide (prekallikrein mRNA degradation)", "academicBackground": "Systems neuroscience: learning, memory, and plasticity"}, {"name": "Jake Wilmot", "startDate": "2024-05-06", "therapeuticArea": "Primary biliary cholangitis (hepatology, rare disease)", "drugNameMoa": "seladelpar, PPAR-delta agonist", "academicBackground": "Systems neuroscience: substance use disorder"}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Atrial fibrillation (RN)", "drugNameMoa": "Edoxaban (Savaysa; Factor Xa)", "academicBackground": "Biomedical Sciences, Public Health"}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Systemic mastocytosis (RN)", "drugNameMoa": "Avapritinib (ayvakit; tyrosine kinase inhibitor)", "academicBackground": "Cell biology"}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Plaque psoriasis (RN)", "drugNameMoa": "Tildrakizumab (Ilumya; IL-23 inhibitor)", "academicBackground": "Opioids"}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Plaque psoriasis; psoriatic arthritis (J&J)", "drugNameMoa": "Guselkumab (Tremfya; IL-23 inhibitor)", "academicBackground": ""}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Crohn's disease; Ulcerative colitis; plaque psoriasis; psoriatic arthritis (JNJ)", "drugNameMoa": "Ustekinumab (Stelara; IL-12 and IL-23 inhibitor)", "academicBackground": ""}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Synovial sarcoma (RN)", "drugNameMoa": "CFT8634 (BRD9 inhibitor)", "academicBackground": ""}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Ulcerative colitis (RN)", "drugNameMoa": "MORF-057 (\u03b14\u03b27 inhibitor)", "academicBackground": ""}, {"name": "Kimberly Dent-Ferguson", "startDate": "2022-07-06", "therapeuticArea": "Graves disease; Rheumatoid arthritis (RN)", "drugNameMoa": "IMVT-1402 (Fcrn inhibitor)", "academicBackground": ""}, {"name": "Stacie Meaux", "startDate": "2024-05-28", "therapeuticArea": "Cardiovascular disease, Bone, Nephrology, Neurology (RN)", "drugNameMoa": "Olpasiran (Lp(a)-targeting siRNA), Repatha (PCSK9 inhibitor), EVENITY (sclerostin inhibitor)", "academicBackground": "RNA metabolism, RNA-based therapeutics, cell biology, cell signaling, gene regulation, cancer biology, immunology, infectious disease, virology"}, {"name": "Lisa Carson", "startDate": "2024-07-01", "therapeuticArea": "Cardiovascular disease (RN)", "drugNameMoa": "Repatha (LDL-C; PCSK9 inhibition)", "academicBackground": "Telomere biology, molecular oncology, evolutionary biology, emergency medicine"}, {"name": "Sefa Basci", "startDate": "2024-05-28", "therapeuticArea": "Gout", "drugNameMoa": "Pegloticase (KRYSTEXXA; PEGylated uric acid specific enzyme)", "academicBackground": "Pharmacology"}, {"name": "Sophia Nies", "startDate": "2024-06-17", "therapeuticArea": "Inflammation (RN)", "drugNameMoa": "apremilast (PDE4 inhibitor); blinatumomab (CD19/CD3 BiTE); inebilizumab (anti-CD19 mAb); avacopan (ANCA-associated vasculitis)", "academicBackground": "Pharmacy"}, {"name": "Sophia Nies", "startDate": "2024-06-17", "therapeuticArea": "Rare diseases (RN)", "drugNameMoa": "donidalorsen", "academicBackground": ""}, {"name": "Shannon Loftus", "startDate": "2024-06-24", "therapeuticArea": "Inflammation (RN)", "drugNameMoa": "OTEZLA/apremilast (PDE4 inhibitor)", "academicBackground": "Immunology, autoimmunity, SLE, CLE, lupus nephritis, dermatology, cell death, nutrition and immunotherapy in prostate and pancreatic cancer"}, {"name": "Sanna Abbasi", "startDate": "2024-05-03", "therapeuticArea": "Oncology (RN)", "drugNameMoa": "Tarlatamab (DLL3 BiTE)", "academicBackground": "Biochemistry (proteomics, genomics, transcriptomics, DNA repair), molecular & cellular biology (epigenetics, genetics), oncology, hematology"}, {"name": "Amy Stewart", "startDate": "2024-05-28", "therapeuticArea": "Oncology (RN)", "drugNameMoa": "Bemarituzumab (anti-FGFR2 mAb)", "academicBackground": "molecular cancer biology, metabolism"}, {"name": "Emily Sechrest", "startDate": "2024-06-17", "therapeuticArea": "Cardiovascular disease, Bone, Nephrology, Neurology (RN)", "drugNameMoa": "Repatha (LDL-C; PCSK9 inhibition)", "academicBackground": "Pharmaceutical Sciences, ophthalmology, retinal cell biology, rod and cone photoreceptors, AAV-mediated gene therapy, subretinal injection, biochemistry, molecular biology, cancer cell biology, breast cancer metastasis to brain, blood-brain-barrier, blood-tumor-barrier"}, {"name": "June Yang", "startDate": "2024-05-28", "therapeuticArea": "Basal cell carcinoma", "drugNameMoa": "Sonidegib (Odomzo; Hedgehog pathway inhibitor)", "academicBackground": "Virology, microbiology, tumor virology, skin cancer, molecular biology, transcription"}, {"name": "June Yang", "startDate": "2024-05-28", "therapeuticArea": "Dry eye disease", "drugNameMoa": "Cyclosporine ophthalmic solution 0.09% (Cequa)", "academicBackground": ""}, {"name": "June Yang", "startDate": "2024-05-28", "therapeuticArea": "Alopecia areata", "drugNameMoa": "Deuruxolitinib (JAK1/JAK2 inhibitor)", "academicBackground": ""}, {"name": "June Yang", "startDate": "2024-05-28", "therapeuticArea": "Skin cancer, solid tumors", "drugNameMoa": "Vusolimogene oderparepvec (RP1, oncolytic immunotherapy)", "academicBackground": ""}, {"name": "June Yang", "startDate": "2024-05-28", "therapeuticArea": "Chronic inflammatory demyelinating polyneuropathy (CIDP)", "drugNameMoa": "Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)", "academicBackground": ""}, {"name": "Alisa Cario", "startDate": "2024-08-05", "therapeuticArea": "Sjogrens Disease (RN)", "drugNameMoa": "Dazodalibep (CD40 antagonist)", "academicBackground": "molecular and cellular biology (cytoskeleton), biochemistry, single-molecule biophysics, neurodegenerative diseases (tauopathies), diabetes, cancer biology"}, {"name": "Alisa Cario", "startDate": "2024-08-05", "therapeuticArea": "Chronic hepatitis B/D infection; chronic herpes virus infection (RN)", "drugNameMoa": "ABI-4334 (core inhibitor, capsid assembly modulator); ABI-6250 (cHDV entry inhibitor)", "academicBackground": ""}, {"name": "Alisa Cario", "startDate": "2024-08-05", "therapeuticArea": "Primary Biliary Cholangitis (RN)", "drugNameMoa": "Seladelpar (PPAR-delta agonist)", "academicBackground": ""}, {"name": "Alisa Cario", "startDate": "2024-08-05", "therapeuticArea": "Cardiovascular disease (RN)", "drugNameMoa": "olpasiran (Lp(a) targetting siRNA)", "academicBackground": ""}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Rare sarcoma: Gastrointestinal stromal tumor (GIST)", "drugNameMoa": "Qinlock (Ripretinib); KIT/PDGFRA tyrosine kinase inhibitor", "academicBackground": "Neuroscience (preclinical); Neuropsychiatric disorders; Substance use disorders (opiods, cocaine, alcohol); Behavioral pharmacology; Sex differences in neurospychatric disorders; Neurodevelopmental disorders; Single-cell and cell-type specific RNA-seq methods; In vivo calcium imaging methods"}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Rare sarcoma: Tenosynovial giant cell tumor (TGCT)", "drugNameMoa": "Vimseltinib; CSF1R inhibitor", "academicBackground": ""}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Oncology: RAS/RAF-mutant cancers", "drugNameMoa": "DCC-3084; pan-RAF inhibitor", "academicBackground": ""}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Virology: Chronic infection with hepatitis delta virus (HDV)", "drugNameMoa": "Hepcludex (bulevirtide), ABI-6250; HDV viral entry inhibtor", "academicBackground": ""}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Virology: Chronic infection with hepatitis B virus (HBV)", "drugNameMoa": "Vemlidy (tenofovir alafenamide), Viread (tenofovir disoproxil fumarate); polymerase inhibitors", "academicBackground": ""}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Oncology: Acute lympholastic leukemia (ALL), non-Hodkin's lymphoma (NHL), multiple myeloma", "drugNameMoa": "Yescarta (axicabtagene ciloleucel); CD-19 CAR-T cell", "academicBackground": ""}, {"name": "Charlotte Pettigrew", "startDate": "2024-06-03", "therapeuticArea": "Oncology: ER+/HER2- breast cancer", "drugNameMoa": "Vepdegestrant; PROTAC ER degrader", "academicBackground": ""}, {"name": "Jordyn Karliner", "startDate": "2024-09-09", "therapeuticArea": "Acne vulgaris", "drugNameMoa": "Clascoterone cream (Winlevi, topical androgen receptor inhibitor)", "academicBackground": "Neurodegenerative diseases"}, {"name": "Jordyn Karliner", "startDate": "2024-09-09", "therapeuticArea": "Alopecia areata", "drugNameMoa": "Deuruxolitinib (JAK1/JAK2 inhibitor)", "academicBackground": "Neuromuscular diseases"}, {"name": "Jordyn Karliner", "startDate": "2024-09-09", "therapeuticArea": "Plaque psoriasis", "drugNameMoa": "Tildrakizumab (Ilumya, anti-IL-23 antibody)", "academicBackground": "Nucleotide repeat expansion disorders"}, {"name": "Genevieve Curtis", "startDate": "2024-03-11", "therapeuticArea": "Rare sarcoma - gastrointestinal stromal tumor (GIST)", "drugNameMoa": "Qinlock (Ripretinib; KIT/PDGFRA tyrosine kinase inhibitor)", "academicBackground": "Neuroscience (preclinical) - diabetes and obesity; eating disorders; subtance use disorders"}, {"name": "Genevieve Curtis", "startDate": "2024-03-11", "therapeuticArea": "Rare sarcoma - tenosynovial giant cell tumor (TGCT)", "drugNameMoa": "Vimseltinib (CSF1R inhibitor)", "academicBackground": ""}, {"name": "Genevieve Curtis", "startDate": "2024-03-11", "therapeuticArea": "RAS/RAF-mutant cancers", "drugNameMoa": "DCC-3084 (pan-RAF inhibitor)", "academicBackground": ""}, {"name": "Genevieve Curtis", "startDate": "2024-03-11", "therapeuticArea": "ER+/HER2- breast cancer", "drugNameMoa": "Vepdegestrant (PROTAC ER degrader)", "academicBackground": ""}, {"name": "Andrey Verendeev", "startDate": "2024-03-11", "therapeuticArea": "Chronic infection with HDV; HEOR and Tx", "drugNameMoa": "Hepcludex (bulevirtide)", "academicBackground": "Neuroscience (behavioral, evolutionary); neuroanatomy; psychopharmacology; animal models of drug taking; substance use disorders; evolutionary analysis of behavior; evolutionary theory; animal behavior"}, {"name": "Andrey Verendeev", "startDate": "2024-03-11", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Vemlidy (tenofovir alafenamide), Viread (tenofovir disoproxil fumarate); polymerase inhibitors", "academicBackground": ""}, {"name": "Andrey Verendeev", "startDate": "2024-03-11", "therapeuticArea": "Chronic infection with HBV", "drugNameMoa": "Selgantolimod; TLR8-agonist", "academicBackground": ""}, {"name": "Rachel Corrigan", "startDate": "2024-09-30", "therapeuticArea": "Hemophilia", "drugNameMoa": "Valoctocogene roxaparvovec (Roctavian; AAV gene therapy)", "academicBackground": "Neuroscience (preclinical) - neurodegenerative diseases and diabetes; pediatric traumatic brain injury; neurodevelopmental disorders; genetics; epilepsies"}, {"name": "Rachel Corrigan", "startDate": "2024-09-30", "therapeuticArea": "Achondroplasia, hypochondroplasia, idiopathic short stature/growth-related conditions", "drugNameMoa": "Vosoritide (Voxzogo; C-type natriuretic peptide (CNP) analogue)", "academicBackground": ""}, {"name": "Rachel Corrigan", "startDate": "2024-09-30", "therapeuticArea": "Phenylketonuria", "drugNameMoa": "BMN 307 (AAV gene therapy)", "academicBackground": ""}, {"name": "Rachel Corrigan", "startDate": "2024-09-30", "therapeuticArea": "Phenylketonuria", "drugNameMoa": "Pegvaliase", "academicBackground": ""}]}